Chromium Depletion and Streptozotocin-induced Diabetes in Pregnancy by Spicer, Maria Teresa Torres
THE EFFECT OF CHROMIUM DEPLETION 
AND STREPTOZOTOCIN-INDUCED 
DIABETES IN PREGNANCY 
By 
MARIA TERESA TORRES SPICER 
Bachelor of Science 
University of the Philippines 
Quezon City, Philippines 
1979 
Master of Science 
Michigan State University 
East Lansing, Michigan 
1984 
Submitted to the Faculty of the 
Graduate College of the 
Oklahoma State University 
in partial fulfillment of 
the requirements for 
the Degree of 
DOCTOR OF PHILOSOPHY 
December, 1996 
THE EFFECT OF CHROMIUM DEPLETION 
AND STREPTOZOTOCIN-INDUCED 
DIABETES IN PREGNANCY 
Thesis Approved: 
-r~Wl/U e. ecRPns 
Dean of the Graduate College 
11 
Dedicated to and in memory of Bernardo F. Caluya 
iii 
ACKNOWLEDGEMENTS 
First, I would like to thank my family: my husband, Leon; my children, Anna, Michael and 
Melissa; my mother, Virginia Caluya Torres; my father, Carlos C. Torres; my uncle, Bernardo F. 
Caluya; my grandfather, Pio Q. Caluya, and the rest of the clan for their endless support and 
patience, and, for believing in me. Most especially, I would like to thank my major adviser and 
committee chairwoman, Dr. Barbara .. J. Stoecker, for her constructive guidance, her calm 
responses, her valuable suggestions, her support which came in many forms and many ways, and, 
for her endless patience and steady keel. Thank you, Dr. Stoecker. 
I am grateful to tlie members of my committee: Dr. Andrea Arquitt, Dr. Lea Ebro and Dr. 
Robert P. Wettemann fot their input towards this dissertation and this graduate degree. Thank 
you, All, for sticking with me. 
I wish to express my sincere gratitude to all those that have helped with this project, most 
especially: Bernice Adeleye, Swama Mandali, Tracey Chen, Emilia Achmadi, Shannon Dougherty, 
Melissa Davis Whitenack, Beth Keefer, Pat Bowen, Pam Ventris, Kerri Shirley, Jarod King, Wen 
Wang and Terra Smith. Thank you. 
Finally, I would like to acknowledge the physical and logistic support of the Department of 
Nutritional Sciences, the College of Human Environmental Sciences, the Animal Science 
Department, the College of Veterinary Medicine Lab Animal Resources, Bruce Nance and Robin 
Guinn, Dr. Joseph McCann and Oklahoma State University. All the labs including the Math 
Science computer lab were invaluable. 
iv 
TABLE OF CONTENTS 
Chapter Page 
I. INTRODUCTION....................................................................................... I 
Research Problem................................................................................ 1 
Objectives and Hypotheses .............. : . . .. . . . . . . . . . . . . .. . . . .. . . . .. . . . . . . . .. .. .. . . .. . .. . .. 3 
Format ofDissertation......................................................................... 5 
II. REVIEW OF 11IB LITERA11JRE . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . .. .. . . . . .. .. . .. . . .. . . .. 6 
Chromium........................................................................................... 6 
Metabolic Characteristics of Pregnancy and 
Gestational Diabetes Mellitus .. .. .. . . . . . . . . . . . . . . . . . .. . .. . . . . . . .. . . . . . . .. . . . . . . . . . . . . . . 15 
The Pregnant Rat Model and the Effects of 
Streptozotocin-Induced Diabetes in Pregnancy................................ 19 
The Insulin-like Growth Factors and 
Their Binding Proteins ..................................................................... 23 
III. METHODOLOGY .......... .......... .. . .... . ........ .. . . . .. ... ............. ..... . . . . . . . . . . . . . . . .. . . . . . 28 
Experimental Design ............................................................................ 28 
Animals and Diets ................................................................................ 29 
Experimental Protocol ......................................................................... 30 
Statistical Analysis............................................................................... 31 
Analytical Methods ................................................................. :............ 3 2 
IV. 11IB EFFECT OF CHROMIUM AND STREPTOZOTOCIN-INDUCED 
DIABETES ON REPRODUCTIVE PERFORMANCE, CARBOHYDRATE 
AND LIPID METABOLISM AND TRACE ELEMENT INTERACTIONS IN 
PREGNAN"CY...... .. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. . . . .. .. .. . . . . . . .. . . . . . . . . .. . . . . .. . . . . . . . . . . . 3 7 
Abstract............................................................................................... 3 7 
Introduction......................................................................................... 3 8 
Research Design and Methods . . .. .. .. .. . . . . . . . . . . . . .. .. .. .. . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . 41 
Results ................................................................................................ 45 
Discussion........................................................................................... 49 
References........................................................................................... 5 3 
V 
Chapter Page 
V. THE EFFECT OF CHROMIUM DEPLETION AND DIABETES ON THE 
MATERNAL AND FETAL INSULIN-LIKE GROWTH FACTOR (IGF) 
SYSTEM AND FETAL GROWTH DURING PREGNANCY..................... 75 
Abstract ......................................................... ~..................................... 75 
Introduction......................................................................................... 7 6 
Research Design and Methods............................................................. 78 
Results ................................................................................................ 80 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 
References........................................................................................... 85 
VI. SUMMARY, CONCLUSIONS AND RECOMMENDATIONS .................. 98 
Summary ............................................................................................. 98 
Conclusions ......................................................................................... 100 
Recommendations ............................................................................... 103 
Implications ......................................................................................... 104 
BIBLIOGRAPHY ...................................................................................................... 105 
APPENDIXES ........................................................................................................... 116 
APPENDIX A - Diet Compositions ..................................................... 117 
APPENDIX B - Mineral Mix Composition .......................................... 118 
·APPENDIX C - Reagents for Hydroxyproline Analysis ........................ 119 
V1 
LIST OF TABLES 
Table Page 
CHAPTER II 
1. Studies of STZ-induced diabetes in pregnant rats .............................................. 22 
CHAPTER IV 
' 
1. Composition of the adaptation and treatment diets used for this study .............. 61 
2. Plasma glucose, insulin, insulin:glucose ratio and glucose tolerance test 
area under the curve (GTTAUC) of normal and STZ-induced 
diabetic dams fed diets with or without added chromium ........................... 62 
3. Total plasma cholesterol, triglycerides, non-esterified fatty acid (NEF A) and 
f3-hydroxybutyrate concentrations of normal and STZ-induced 
diabetic dams fed diets with or without added chromium ........................... 63 
4. Pregnancy outcome of normal and STZ-induced diabetic dams fed diets 
with or without added chromium ............................................................... 64 
5. Weights and percent bodyweight of various tissues from normal and · 
STZ-induced diabetic dams fed diets with or without added chromium ...... 65 
6. Liver moisture, fat and protein concentration of normal and STZ-induced 
diabetic dams fed diets with or without added chromium ........................... 66 
7. Chromium concentration (µmol/k:g dry weight) of various tissues from normal 
and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 67 
8. Manganese concentration (µmol/k:g dry weight) of various tissues 
from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 68 
vii 
Table Page 
9. Copper concentration (mmol/kg dry weight) of various tissues 
from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 69 
10. Zinc concentration (mmol/kg dry weight) of various tissues 
from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 70 
11. Iron concentration (mmol/kg dry weight) of various tissues 
from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 71 
12. Calcium concentration (mmol/kg dry weight) of various tissues 
. from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 72 
13. Magnesium concentration (mmol/kg dry weight) of various tissues 
from normal and STZ-induced diabetic dams fed diets with 
or without added chromium ....................................................................... 73 
CHAPTER V 
1. Diet compositions· ............................................................................................. 91 
2. Pregnancy outcome of normal and STZ-induced diabetic dams fed diets 
with or without added chromium ............................................................... 92 
3. Plasma insulin, glucose, IGF-1 & IGF-11 from normal and STZ-induced 
diabetic dams fed diets with or without added chromium ........................... 93 
4. IGF binding protein activity from plasma of normal and STZ-induced 
diabetic dams fed diets with or without added chromium ........................... 94 
5. IGF binding protein activity from plasma of fetuses from normal and 
STZ-induced diabetic dams fed diets with or without added chromium ...... 95 
6. Plasma insulin, glucose, IGF-1 & IGF-11 concentrations of fetuses 
from normal and STZ-induced diabetic dams fed diets 
with or.without added chromium ............................................................... 96 
viii 
LIST OF FIGURES 
Figure Page 
CHAPTER IV 
1. Glucose tolerance curves of normal and STZ-induced diabetic dams 
fed diets with or without added chromium (Cr)., ........................................... 74 
CHAPTER V 
1. A representative ligand blot analysis ofIGFBP activity in maternal and 






























Estimated Safe and Adequate Daily Dietary Intake 
gestational diabetes mellitus 
general linear models 
glucose tolerance factor 
glucose tolerance test 
high density lipoproteins 
insulin-like growth factors 
IGF binding proteins 
kilo Dalton 
low density lipoproteins 
lipoprotein lipase 
lithium hydroxide 
Recommended Dietary Allowances 
Statistical Analysis System 
Sprague-Dawley 
small for gestational age 
streptozotocin 
total parenteral nutrition 





Numerous metabolic changes related to nutrition occur in normal uncomplicated 
pregnancy. Insulin resistance increases and glucose tolerance decreases. This is 
manifested by elevated blood insulin concentrations which maintain blood glucose within 
normal limits (1 ). As pregnancy progresses, lipid metabolism is altered such that 
lipogenesis is favored early in pregnancy but not in late pregnancy. In late gestation, 
decreased lipoprotein lipase activity (LPL) in adipose tissue and increased triglyceride 
production by the liver result in hypertriglyceridemia. Before parturition, LPL activity in 
the mammary glands increases utilizing circulating triglycerides for milk production (2). 
1 
Gestational diabetes, mellitus (GDM) is impaired glucose intolerance of varying 
severity first diagnosed during pregnancy (3). High perinatal risks such as premature 
birth, infant morbidity and mortality, macrosomia, congenital abnormalities and obstetric 
complications such as urinary tract infections, polyhydramnios, pre-eclampsia and toxemia 
result from uncontrolled GDM as well as from poorly managed diabetes in pregnancy 
(4,5). In the early 1980's, GDM was a global problem that developed in 2-3% of all 
pregnancies (6). In 1988, 4% of all pregnancies that resulted in live birth in the United 
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States were complicated with diabetes. Of these 154,000 pregnancies, 88% were 
complicated by gestational diabetes mellitus, 8% by pre-gestational non-insulin dependent 
diabetes and 4% by pre-gestational insulin dependent diabetes (7). Congenital 
malformations, stillbirth and neonatal death still occur despite more intensive prenatal care 
for the diabetic pregnant woman (8). 
Maternal nutrition is a significant contributor to the outcome of pregnancy. Most 
mothers with GDM can achieve good metabolic control by only modifying their diets. 
Some require supplemental insulin to help control glucose concentrations in the blood. 
Insulin dependent diabetic mothers may have a more difficult time with glucose control 
resulting in large fluctuations in blood glucose and unpredictable reactions to insulin 
especially in adolescent pregnancy. Adequate chromium in the diet may potentiate the 
action of insulin especially in those individuals who have suboptimal intakes of the trace 
mineral. The analysis of freely chosen and institutional composite diets showed that even 
well planned diets contain less than the recommended estimated safe and adequate daily 
dietary intake of 50 µg chromium per day (9). Dietary chromium supplementation of 
patients, subjects and experimental animals presumed to be deficient in chromium has been 
shown to improve glucose tolerance and decrease the need for exogenous insulin (10 -
14). The effect of supplemental dietary chromium in promoting better glucose control and 
minimizing the need for exogenous insulin in pregnant women that have difficulty 
achieving normal glucose homeostasis has not been studied (15). 
In murine pregnancy, the insulin-like growth factors (IGF's) are necessary for 
embryogenesis and fetal growth (16 - 19). Streptozotocin induced diabetic pregnancies in 
rats resulted in impaired fetal growth (20 - 22). Chromium deficient mature rats are 
growth retarded compared to rats fed chromium (23). Growth retarded fetal rats had 
decreased IGF-I and -II gene expression, decreased fetal serum IGF-1 and increased 
IGFBP-1 gene expression (24 - 26). Decreased serum IGF-I, differential gene expression 
oflGF-1 and IGFBP-1 as well as discordant organ specific regulation ofIGF-I mRNA 
have been observed in streptozotocin induced diabetic male rats and non-pregnant female 
rats (27 - 29). In adult streptozotocin diabetic male Sprague Dawley rats, renal IGF-I 
accumulation occurred despite a reduction in plasma IGF-1 concentrations (30). The 
effect of streptozotocin diabetes as well as dietary chromium on the IGF system has not 
been studied in pregnant rats. 
Diabetes mellitus results in the alteration of micronutrient status (31). Abnormal 
trace element metabolism occurs in diabetic rat dams and their fetuses (20 - 33). 
Manganese, copper and zinc accumulated in the liver and kidneys of diabetic dams. 
Compared with normal controls, fetuses of diabetic dams have low levels of liver zinc and 
elevated levels ofliver manganese. In the placenta, copper, magnesium and calcium are 
reduced. The effect of chromium on macro- and micromineral distribution in the tissues 
and its interactions with other microminerals has not been studied in the STZ-induced 
diabetic pregnant rat model. 
Objectives and Hypotheses 
The first objective of this study was to determine the effect of chromium depletion 
and diabetes induced during pregnancy on glucose tolerance, and on circulating total 




Null Hypothesis: Chromium depletion and diabetes during pregnancy do not affect 
maternal glucose tolerance or total plasma cholesterol, triglycerides, non-esterified fatty 
acids and J3-hydroxybutyrate concentrations. 
The second objective of this study was to determine the effect of chromium 
depletion and diabetes induced during pregnancy on plasma insulin, glucose, IGF-I, 
IGF-II, maternal weight gain and pregnancy outcome. 
Null Hypothesis: Chromium depletion and diabetes during pregnancy do not affect 
maternal plasma insulin, glucose, IGF-1, IGF-II, maternal weight gain or pregnancy 
outcome. 
The third objective of this study was to determine the effect of chromium depletion 
and diabetes during pregnancy on fetal plasma insulin, glucose, IGF-I, IGF-II, fetal 
weight, fetal protein and hydroxyproline concentrations. 
Null Hypotheses: Chromium depletion and diabetes during pregnancy do not 
affect fetal plasma insulin, glucose, IGF-I, IGF-II, fetal weight, fetal protein or 
hydroxyproline concentration. 
The fourth objective of this study was to determine the effect of chromium 
depletion and diabetes during pregnancy on macromineral and trace mineral 
concentrations in the liver, kidney, spleen, heart, placenta and fetuses of the experimental 
animals. 
Null Hypotheses: Chromium depletion and diabetes during pregnancy do not 
affect macromineral and trace mineral concentrations in the liver, kidney, spleen, heart, 
placenta and fetuses of the experimental animals. 
Format of Dissertation 
This dissertation will contain six chapters: the introduction, literature review, 
methodology, two journal articles and a conclusion. All chapters will be formatted 
according to the recommended manuscript preparation style required by Diabetes, the 




REVIEW OF THE LITERATURE 
Chromium 
The trace mineral, chromium, has effects on both glucose and lipid metabolism. 
Chromium deficiency in man and animals is associated with impaired glucose tolerance 
and a syndrome simulating diabetes mellitus (23,34). Fasting hyperglycemia and 
glycosuria have been observed in rats with an intake of O .17 µg chromium per gram diet 
(34). Severe chromium deficiency in rats leads to retarded growth, decreased glycogen 
reserves, increased incidence of aortic lesions and disturbances in amino acid utilization for 
protein synthesis (23). In patients receiving total parenteral nutrition, symptoms of insulin 
resistance, hyperglycemia and diabetic neuropathy were alleviated by chromium 
supplementation (10, 11, 35). 
Two considerations need to be made in evaluating chromium studies: accuracy and 
experimental protocols utilizing different.dietary sources for chromium. Through the 
years, analytical methods and handling of samples for chromium analysis have improved. 
Due to these improvements, reported values for chromium concentrations in tissues, urine 
and blood have decreased to trace or micro concentrations. Contamination is a problem in 
chromium analysis and has to be considered throughout this review. It is assumed that the 
studies mentioned herein had good controls and that all samples within each study were 
handled in a consistent manner. Mertz recommends that analytical values for chromium 
reported before 1980 should not be accepted (15) because values reported then were too 
high compared with values that have been confirmed more recently with improved 
analytical knowledge and capabilities (36). The other consideration in evaluating 
chromium studies is the different dietary sources of chromium which have been used in 
different experimental protocols. A preliminary study by Ward et al (37) has determined 
that there were no significant differences in the effects of chromium chloride (CrCh), 
chromium acetate, chromium oxalate, chromium nicotinate, chromium picolinate (CrPic) 
or chromium nicotinate-glycine"'.'.cysteine-glutamate on growth, carcass characteristics, 
plasma metabolites or hormones in growing finishing pigs. The following section will 
discuss common thoughts and observations that have arisen regarding chromium's 
physiological effects despite differences in dietary sources of chromium, time and 
experimental protocols. 
Effects of chromium on glucose tolerance 
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Glucose tolerance may be defined as the body's ability to maintain normal blood 
glucose concentrations in the post-absorptive state as well as postprandially or after a 
glucose load. Three case reports document the positive effect of chromium 
supplementation on glucose tolerance in patients receiving total parenteral nutrition (TPN) 
that were observed to have low levels of plasma chromium. In one case (10), a patient 
who had been on a TPN regimen for 3 1/2 years without any problem suddenly lost weight 
and exhibited symptoms of peripheral neuropathy and glucose intolerance. Weight loss 
and neuropathy persisted despite the addition of insulin to her treatment. The addition of 
250 µg chromium to the TPN solution daily for two weeks abolished the need for insulin. 
Thereafter, the patient was maintained on 20 µg chromium per day and insulin was no 
longer needed. Freund and colleagues (11) reported a similar case with a patient that had 
a complete bowel resection and had been on TPN for 5 months. The patient developed 
severe glucose intolerance, weight loss and metabolic encephalopathy. Chromium 
supplementation improved glucose tolerance, reduced insulin requirements and resulted in 
weight gain. The third case report involved a patient with short bowel syndrome 
following a resection who required TPN. The patient presented with similar symptoms as 
the previous cases and was given additional chromium in the TPN solution. Ten days 
after initiating chromium supplementation, the patient no longer required insulin and was 
maintained on 26 µgadded chromium per day (35). 
In 1966, Glinsman and Mertz (38) reported that 3 out of 6 subjects with maturity 
onset diabetes responded to 180 µg chromium per day from CrCh supplementation with 
improved glucose tolerance. Supplementation with 150 - 1000 µg chromium per day of 
10 non-diabetic subjects with normal glucose tolerance tests did not alter their responses 
except for one person with a positive family history of diabetes who had reactive 
hypoglycemia. In this one case, chromium supplementation was associated with an 
improved glucose tolerance curve. 
Chromium supplementation with 200 µg chromium from CrCh improved glucose 
tolerance only in patients with marginal hyperglycemia and reactive hypoglycemia but not 
in normal healthy individuals. Anderson et al (39) observed that chromium 
supplementation of normal, free living subjects significantly decreased fasting and 90 
8 
minute glucose concentrations in response to a 1 g/kg glucose challenge in those subjects 
whose serum glucose concentrations were equal to or greater than 100 mg/dL 90 minutes 
after the glucose challenge. Subjects whose 90 minute concentrations were at or below 
their fasting levels did not show a similar response to chromium supplementation. In a 
later study (13), subjects who consumed controlled low chromium diets were treated with 
chromium supplementation or placebo in a double blind crossover design. Chromium 
supplementation did not change glucose tolerance or insulin responses of normal, healthy 
subjects while the same parameters were improved in hyperglycemic subjects whose diets 
were supplemented with 200 µg chromium from CrCh per day. The Estimated Safe and 
Adequate Daily Dietary Intake (ESADDI) for chromium set by the National Research 
Council is 50 - 200 µg/day (40). 
In pigs, dietary chromium supplementation from CrPic in conjunction with 
pituitary porcine growth hormone reduced the increase in blood glucose and insulin 
concentrations induced by growth hormone treatment (41). In another study (42), 
barrows fed 200 µg Cr/kg diet as CrPic had reduced fasting plasma insulin compared with 
controls. In response to intravenous glucose tolerance tests, the chromium fed barrows 
had a greater glucose clearance rate and a shorter serum glucose half-life. In response to 
an insulin challenge, glucose clearance rates were greater in the chromium fed group. In 
pregnant sows, insulin response to feeding was significantly less in animals fed diets 
supplemented with 200 µg Cr/kg diet from CrPic compared with unsupplemented 
pregnant sows (43). 
9 
10 
Urinaiy chromium excretion 
Morris and colleagues ( 44, 45) studied the effect of 75 g oral glucose on plasma 
chromium, glucose, insulin and urinary chromium excretion in normal, healthy adults. 
They observed that along with the normal glucose and insulin response to the glucose 
challenge, plasma chromium had a significant inverse relationship with plasma insulin and 
that urinary chromium concentrations increased between 30 - 60 minutes after the 
challenge. The inverse relationship between plasma insulin and plasma chromium was also 
noted when diurnal measurements were plotted. These patterns of urinary chromium 
excretion are similar to those observed in earlier studies by Gurson and Saner (46, 47). In 
normal adults, they noted a significant increase in urinary chromium excretion at the end 
of the 75 g oral glucose tolerance test compared with concentrations before the test (46). 
Contrary to these observations, Anderson and coworkers ( 48) did not find any significant 
difference between urinary chromium excretion before and after glucose loading in 
placebo or chromium supplemented subjects. However, they did observe a significant 
difference in urinary chromium excretion between the groups at fasting at the beginning of 
the study. 
Possible mechanisms for chomium's insulin potentiating effect 
Natural or synthetic glucose tolerance factor (GTF) has been shown to potentiate 
the action of insulin ( 49). Insulin potentiation is expressed as the ratio of radioactive CO2 
produced from fat cell oxidation of radio labeled glucose at a fixed concentration of insulin 
with added GTF to that produced without the addition of GTF. The addition of 
increments of GTF alone to basal concentrations of insulin (i.e., no insulin added to the 
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media) increased CO2 production and achieved maximum response. (V max) without the 
addition of insulin. Dietary chromium supplementation by reactive hypoglycemic subjects 
increased insulin binding and receptor number but not affinity (50) while chromium 
supplementation by normal control subjects did not show any alterations in receptor 
binding, receptor number or affinity. 
CrPic increased insulin receptor complex internalization rate accompanied by a 
marked increase in glucose and leucine uptake (51). Insulin receptor internalization was 
determined by a modified (125I)insulin receptor assay utilizing trypsin to release 
internalized radioactive insulin. Data were not corrected for non-specific binding but the 
results indicated that both the quantity of initially bound insulin receptors and insulin 
internalization were significantly greater in muscle cells precultured with CrPic. 
Mouse myotubes cultured in low chromium media had a decreased glucose uptake 
response to insulin (52). As demonstrated by dose response curves, these cells had greater 
sensitivity to insulin in the presence of chromium. Glucose uptake was measured by 
monitoring 2-deoxy-{ 1-H3}glucose. In vitro studies show that 51CrCh uptake by muscle 
and adipose tissue was glucose dependent and was blocked by the glucose transport 
inhibitors, phloretin, phloridzin and cytochalasin b (53). 
The effect of diabetes on chromium status and metabolism 
Gurson and Saner ( 46) studied the effect of a glucose challenge on the urinary 
excretion of chromium by diabetic subjects and individuals with a family history of 
diabetes. In 8 out of 10 normal adults, urinary chromium excretion increased significantly 
after an oral glucose tolerance test but only 3 out of 8 diabetic subjects and 5 of 15 
subjects with a family history of diabetes had a similar response. In diabetic subjects, 
Morris and colleagues (44, 54) observed that plasma chromium concentrations were 
significantly lower than in normal healthy individuals and that there was a significant 
positive correlation between urinary chromium excretion and urinary glucose as well as 
the duration of diabetes. Twenty-four hour urinary chromium excretion of the diabetic 
subjects was three times greater than that of the normal controls (44). Doisy and 
colleagues (55) observed that 51chromium absorption was three times greater in diabetics 
than in normal controls. This suggests that diabetic individuals may have an increased 
requirement for chromium due to a negative chromium status. 
Chromium status in pregnancy and gestational diabetes mellitus 
12 
Data are limited and archaic on the chromium status of normal pregnant and GDM 
women. Plasma chromium was significantly lower in pregnant women compared with 
non-pregnant women (56). Multiparous women had lower hair chromium content 
compared with nulliparous women (57 - 59). Hair chromium content decreased as 
gestation progressed (59, 60) while urinary chromium excretion increased concommitantly 
(61). In response to i.v. as well as oral glucose challenges, plasma chromium decreased in 
normal non-pregnant women but not in pregnant women (56). In rats, the fetoplacental 
uptake of 51chromium accounts for 25 to 30% of the 51chromium retained by the mother 
(62). These observations suggest that chromium status is greatly compromised during and 
by gestation. 
Chromium status may influence insulin sensitivity during pregnancy as well. 
Gestational diabetic women had significantly greater hair chromium content than normal 
13 
pregnant women (60). It was suggested that gestational diabetic women had a "chromium 
resistance" that resulted in higher hair chromium concentrations but plasma chromium was 
not measured in the subjects to confirm this theory. It is more conceivable, based on the 
research by Morris and colleagues (53), that chromium excretion and hair chromium 
') 
content would be greater in glucose intolerant subjects due to decreased glucose 
dependent chromium uptake by insulin dependent tissues. 
Studies on the effects of chromium supplementatioin on reproductive performance 
in pigs are inconclusive. In one study, Lindemann et al (43) observed significantly larger 
litter sizes in chromium supplemented sows. But in a following study ( 63 ), litter size was 
not significantly different between the supplemented and unsupplemented group. 
Although it was not statistically significant, the researchers did point out that there was an 
average of one more live pig per litter in the supplemented group. 
Effect of chromium on lipid metabolism 
The effect of chromium on plasma lipids are not in agreement but there are more 
studies that demonstrate a lipid lowering effect. In 1965, Schroeder (34) observed a lower 
incidence of aortic plaques (2%) in chromium fed rats than in chromium deficient rats 
(19%). In hypercholesterolemic rats, Staub et al (64) noted a significant decrease in 
serum cholesterol after the addition of chromium acetate to the drinking water of the 
experimental group. Both synthetic and naturally occurring GTF lowered plasma 
triglycerides in normal and genetically diabetic mice {65). In chromium deficient rats, 
supplementation with high chromium baker's yeast lowered both serum cholesterol and 
triglyceride concentrations while supplementation with CrCh decreased only serum 
triglycerides (66). 
Elderly subjects whose diets were supplemented with chromium-rich yeast had 
decreased serum cholesterol and total lipids compared with those that received low-
chromium yeast supplemetation (67). In a subsequent study by the same research group 
(68), however, no significant effects of chromium supplementation on blood lipids were 
observed. 
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Chromium treated atherosclerotic rabbits had a significant reduction in aortic 
plaque and aortic cholesterol content compared with controls (69). HDL cholesterol 
increased and serum triglycerides decreased in human subjects with established 
atherosclerotic disease treated daily with 5 µmols (260 µg) chromium from CrCh (70). In 
adult men, HDL cholesterol increased when they received 4 µmols (200 µg) chromium per 
day from CrCh supplementation (71 ). Responses were more pronounced in the insulin 
resistant subjects. Both total cholesterol and the total cholesterol:HDL cholesterol ratio 
decreased significantly in male athletes given 4 or 8 µmols (200 or 400 µg) chromium 
daily from a chromium-nicotinic acid complex (72). 
Hermann and colleagues observed that in elderly subjects with total cholesterol 
concentrations greater than 6.21 mM (240 mg/dL), supplemental CrCh (4 µmols daily) 
decreased LDL cholesterol, total cholesterol and apoprotein B concentrations (73). 
Chromium supplementation did not affect HDL cholesterol, serum triglycerides or glucose 
concentrations. 
Metabolic Characteristics of Pregnancy and Gestational Diabetes Mellitus 
A shift in energy substrate metabolism related to hormonal and other physiological 
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changes normally occurs during pregnancy. In normal uncomplicated pregnancies, insulin 
resistance characterized by an elevated insulin response to a glucose challenge which 
maintains blood glucose concentrations within accepted normal limits develops in the later 
half of gestation. In gestational diabetes, individuals are unable to respond as well to a 
glucose challenge resulting in elevated blood glucose concentrations despite the elevated 
insulin response (1). There is a normal increase in blood lipids especially after mid-
gestation. Serum triglycerides increase two to threefold reaching an average peak in the 
range of2.26 - 3.39 mmol/L (200 to 300 mg/dL) at term while total cholesterol 
concentrations increase by an average of 50% reaching an average peak in the range of 
5.17 - 6.46 mmol/L (200 to 250 mg/dL) at term (74). Significant positive predictors of 
birth size include: maternal age, prepregnancy weight, pregnancy weight gain, plasma 
glucose, plasma insulin, human placental lactogen, and estriol (75). Serum creatinine on 
the other hand is a negative predictor of birth weight. As serum creatinine concentration 
increases birthweight decreases. 
Gestational diabetes mellitus is associated with a 35 - 38% rate of Cesarean 
sections, 17 - 33% rate ofmacrosomia, a 7 - 13% incidence of shoulder dystocia and a 28 
- 30% incidence of the requirement for exogenous insulin (76). The American Diabetes 
Association mandates that all pregnant women be screened for gestational diabetes 
mellitus (3). Pre-conception planning and care are strongly recommended for pre-
gestational diabetic women. Gestational diabetes mellitus is diagnosed when two or more 
blood glucose values during a glucose tolerance test are above the following parameters: 
5.6 mM (105 mg/dL) fasting, 10.6 mM {190 mg/dL) 1 hour after a 100 gram glucose 
load, 9.2 mM (165 mg/dL) 2 hours postload and 8.1 mM (140 mg/dL) 3 hours post load 
(3). 
The following section will discuss the insulin resistance of normal pregnancy, the 
metabolic characteristics of normal pregnant women and contrast these normal 
characteristics to those of gestational diabetic pregnant women. 
Insulin resistance in normal pregnancy and in gestational diabetes 
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In normal pregnant women, fasting plasma insulin concentration increases 
gradually as gestation progresses (77). At term, these levels are almost double pre-gravid, 
post partum or non-pregnant concentrations (78 - 80). In normal pregnant women, insulin 
resistance is manifested by blood glucose concentrations which are maintained within 
normal limits by elevated insulin concentrations (1). The insulin resistance or decreased 
insulin sensitivity of pregnancy is further demonstrated by a magnified insulin response to 
a glucose load such that the area under the insulin response curve is much greater in 
pregnancy than in the non-pregnant state (77,80 - 82). The insulin to glucose ratio is also 
much greater in pregnancy than in the non-pregnant state (83). 
Euglycemic hyperinsulinemic clamp studies in normal pregnant women show that 
there is a 27 - 56% decrease in insulin sensitivity at 36 weeks gestation compared with the 
non-pregnant state (83,84). Clamped at I 00 µU/mL of circulating insulin, women in late 
gestation required a glucose infusion rate of 4.6 ± 1.3 mg glucose/kg fat-free body 
mass/min to maintain a blood glucose concentration of 5.0 mmol/L (90 mg/dL) while their 
pregravid infusion rate was 10.5 ± 2.7 mg/kg fat-free mass/min (83). Non-pregnant non-
diabetic controls in another study clamped at an infusion rate of 240 mU/m2/min insulin 
required a glucose infusion rate of 372 ± 11 mg/m2/min to maintain a blood glucose 
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concentration of 4.2 mmol/L (75 mg/dL) while pregnant non-diabetic women required 270 
± 31 mg/m2/min to maintain the same blood glucose concentration (84), a 27% decrease in 
glucose infusion rate. 
In contrast, gestational diabetic women respond to a glucose challenge with a 
higher response curve resulting in a larger area under the curve (AUC) compared with 
normal pregnant women in late gestation (81 ). Under fasting conditions, gestational 
diabetic women have higher circulating concentrations of blood glucose, insulin, free fatty 
acids and f3-hydroxybutyrate compared with normal pregnant women (85). Diurnal 
glucose concentrations were higher in GDM women than in normal pregnant women (86) 
and were consistently above normal pregnant values. 
The mean insulin response to a glucose challenge was significantly lower in 
gestational diabetic women compared with normal pregnant controls. In a study by 
Buchanan and colleagues (79), first phase insulin responses by 80% of the GDM women 
in their study were below the 95% CI of the mean response of normal pregnant women. 
Under euglycemic hyperinsulinemic conditions, GDM women require an even lower 
glucose infusion rate (157 ± 26 mg/m2/min) than normal pregnant women (270 ± 31 
mg/m2/min) representing a 42% decrease in glucose infusion rate compared with normal 
pregnant women and a 58% decrease in glucose infusion rate compared with normal non-
pregnant women demonstrating a more profound insulin resistance or an impaired 
responsiveness to the action of insulin in gestational diabetes mellitus (84). 
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Hyperlipidemia of nonnal pregnancy 
In addition to insulin resistance, hyperlipidemia is another nonnal characteristic of 
late pregnancy. Total plasma triglycerides increased two to threefold ofprepregnancy 
values while total plasma cholesterol increased by 50 - 60% of prepregnancy values 
(74,87,88). In a survey of 553 women, the mean total plasma triglyceride concentration at 
36 weeks gestation was 2.6 ± 0.9 mmoJ/L (227 ± 84 mg/dL) compared with a mean of0.7 
± 0.3 mmoJ/L (64 ± 27.6 mg/dL) in 100 non-pregnant non-honnone users (89). Mean 
total plasma cholesterol for the pr~gnant women was 6.4 ± 1.1 mmol/L (247 ± 42 mg/dL) 
compared with a mean of 4.4 ± 0.7 mmol/L (169 ± 28.8 mg/dL) in the nonpregnant 
women. Very low density lipoprotein triglyceride concentrations were three times greater 
and LDL triglycerides four times greater in the pregnant women than in the nonpregnant 
women while VLDL cholesterol was double and LDL cholesterol 50% more in the 
pregnant women compared with the nonpregnant women. Similar concentrations for 
lipoprotein lipid fractions have been observed by Montelongo and colleagues (90). 
Fahraeus et al observed that total plasma cholesterol increased gradually through 
pregnancy up to 54% above early pregnancy values (91). LDL cholesterol followed a 
similar pattern increasing to 56% above early pregnancy values. HDL cholesterol peaked 
at 28% above early pregnancy values at 28 weeks gestation. VLDL cholesterol rapidly 
increased at 20 weeks gestation and peaked at 36 weeks, increasing to almost 200% above 
week 20 values. All these lipid parameters declined after delivery. Similar patterns have 
. been noted by Potter et al (87) and Desoye et al (92). 
Desoye and coworkers found a significant positive correlation between estradiol, 
19 
progesterone and human placental lactogen, and total cholesterol, free cholesterol, 
phospholipids and total triglycerides during pregnancy in women (92). Total triglyceride 
concentrations were correlated positively with insulin while Apo-B was positively 
correlated with estradiol. The strongest correlation was between total triglycerides and 
progesterone. Knopp and colleagues found a positive correlation between VLDL 
triglycerides and insulin, total triglycerides and estriol and HDL cholesterol with estradiol 
and progesterone (93). In another study, a positive linear semilogarithmic relationship 
was observed between plasma lipoprotein triglycerides and estradiol, progesterone and 
prolactin in pregnancy (90). 
Diurnal plasma triglyceride concentrations were consistently greater in GDM 
women than in normal pregnant women during late gestation (86). Throughout gestation, 
GDM women and pre-gestational diabetic women had higher plasma free fatty acids 
compared with normal pregnant controls (90). Total plasma triglycerides and cholesterol 
concentrations were not different between normal and diabetic groups while 
concentrations of LDL triglycerides, LDL cholesterol, LDL phospholipid and HDL 
phospholipid were consistently less in GDM women (90). 
The Pregnant Rat Model and STZ Diabetes in Pregnancy 
The normal pregnant rat model 
Reduced insulin sensitivity similar to that in humans is also evident in the pregnant 
rat (94). In the fed state, plasma glucose of the pregnant rats was lower than virgin 
controls while insulin was greater in the pregnant rats than in the virgin controls (95, 96). 
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Insulin to glucose ratios in the pregnant rat were greater than virgin controls as well. 
Insulin secretion in response to intravenous glucose in late gestation (19-21 days in the 
rat) was significantly greater than in early pregnancy (97). Glucose infusion rates under 
hyperinsulinemic euglycemic clamp experiments were lower in pregnant rats than in virgin 
controls to maintain euglycemia under hyperinsulinemic conditions. Insulin secretion in 
response to intravenous glucose in the 19 and 21 day pregnant rat was significantly 
increased compared with virgin controls (98). Given a low dose of insulin (50 - 150 
mU/kg body weight), a smaller hypoglycemic response was observed compared with 
virgin controls while a large dose of insulin (4 U/kg body weight) produced a normal 
hypoglycemic response in the late pregnant rat. 
Plasma triglycerides increased two to threefold during pregnancy in rats (99,100). 
The disappearance oflabeled chylomicron triglycerides was slower in late pregnancy than 
during the first half of gestation (99). In addition to elevated total plasma triglycerides, 
total cholesterol, chylomicron triglycerides, and VLDL triglycerides and cholesterol were 
greater while LDL triglycerides and cholesterol were less in late pregnant rats compared 
with non-pregnant·controls. Concentrations of adipose tissue free fatty acids were greater 
in pregnant rats compared with nonpregnant controls (101). Maternal lipid storage 
declined in late gestation (102). Maternal carcass fat content increased until day 19 of 
pregnancy then decreased significantly until term (103). 
The STZ-induced diabetic pregnant rat model 
Scientists have chemically induced diabetes in pregnant rats with STZ since 1969. 
Streptozotocin was an antibiotic isolated from Streptomyces achromogens which was 
found to be diabetogenic in rats by the action of selectively destroying the j3-cells of the 
pancreas. It was found to be less fatal and toxic than alloxan (132). 
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Table II. I summarizes different protocols that have been used for the induction of 
diabetes in pregnancy using STZ. Despite these differences in methods, several common 
observations can be made. Diabetic pregnant rats gained less weight, were hypo-
insulinemic and hyperglycemic compared with non-diabetic pregnant controls. Their 
insulin to glucose ratios were lower than normal pregnant rats (21,104). Only a few 
studies showed no difference in litter size between diabetic and normal controls (21,105) 
while the others reported a significantly smaller number of fetuses per litter. STZ diabetic 
dams had smaller fetuses compared with non-diabetic dams and had a greater incidence of 
malformations. Streptozotocin diabetes in pregnancy induced a significant increase in 
total plasma triglycerides (21,93,106) and plasma j3-hydroxybutyrate (106) and a decrease 
in plasma free fatty acids (106). Streptozotocin diabetic dams as well as their fetuses had 
a lower concentration of circulating total amino acids (107). Furthermore, the rate of 
protein synthesis in diabetic dams and their fetuses was lower than non-diabetic controls 
while maternal liver RNA concentration was decreased and fetal liver RNA content 
increased (108). 
Streptozotocin diabetic dams had larger livers, kidneys and placentas compared 
with non-diabetic controls (20). Liver and kidney zinc and copper were elevated in 
diabetic dams compared with non-diabetic dams (20,32,33,109). In addition, maternal and 
fetal liver manganese and fetal liver iron increased while fetal liver zinc, placental 
magnesium and calcium and maternal kidney calcium decreased (20). 
Table 11.1 
Studies of STZ-induced diabetes in pregnant rats . 
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Authors DoseNehicle Site/ When given Strain/ Weight or n Scope of Study 
Age 
... --· ···•-·'"'"" ..... ··~··· .. ·- ···--·····-·"··--·-···"··········· 
Sybulksi (1971) (105) 50mg/kg BW in citrate Tail vein/ 6 - 9 days Wistar/ 225 grams 93 Compared with alloxan treatment 
buffer gestation 
Golob (1971) (133) 30 - 50 mg/kg BW in Tail vein/ 5 days gestation SD*/ 160 - 190 141 Effect on fasting vs non-fasting 
citrate buffer grams blood glucose concentration 
Eriksson (1980) (104) 20 - 50 mg/kg BW in I.V./ 2 weeks before SDI 250 grams 173 Effect on fetal growth 
citrate buffer breeding 
Triadou (1982) (134) 100 µgig BW in citrate Saphenous vein/ at birth Wistar bred at 2 18 Effect on glucose tolerance 
buffer months 
Eriksson (1984) (33) 45 - 50 mg/kg BW in I.V./ 2 weeks before SDI 250 grams 50 Effect on fetal outcome and 
citrate buffer breeding maternal and fetal liver zinc, 
copper and manganese 
Uriu-Hare ( 1985) (20) 40 - 45 mg/kg BW in Tail vein/ 2 weeks before SD vs Wistar/ 250 60 Effect on tissue distribution of 
citrate buff er breeding -275 grams mineral 
Aerts (1989) ( 107) 22.5 & 30 mg/kg BW Tail vein/ Day l gestation Wistar/ 200 grams ? Effect on amino acids 
Martin (1991) (106) 45 mg/kg BW in citrate l.P./ l week before Wistar/ 160 - 180 ? Effect on blood lipids 
buffer breeding grams 
Uriu-Hare (1992) (109) 40 mg/kg citrate buffer Subcutaneous/ I - 2 weeks 210 - 220 grams 38 Effect on zinc and copper 
before breeding 
Martin (1995) (108) 40 mg/kg BW in citrate l.P./ l week before Wistar/ 160 - 180 500 Polysomal aggregations and rate of 
buffer breeding grams protein synthesis 
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* SD = Sprague-Dawley N 
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The Insulin-like Growth Facton (IGF's) and Their Binding Proteins (IGFBP's) 
Insulin-like growth factors for embzyo development and fetal growth 
The uterine environment for the pre-implantation rodent embryo is rich in both 
IGF's and IGFBP's (16). Diverse expression of the IGF-1 and IGF-II gene and the IGF 
binding proteins occurs throughout murine embryonic development (110, 111). The 
mouse embryo expresses IGF-Il receptor transcripts as early as the 2 cell stage, and IGF-I 
and insulin receptor transcripts at the 8 cell stage (18, 19). IGF-II is highly abundant in 
trophoblast derived cells of the rat placenta throughout gestation except at the junctional 
zone immediately before term (112). In the 20 day old fetus, serum IGF-II concentrations 
are 6 -7 times greater than IGF-1 (24, 113). Marked fetal growth retardation occurred in 
mice with a hemizygous disruption of the IGF-Il gene (114) indicating that IGF-II had a 
more important role than IGF-I in fetal growth. In situ hybridization studies showed that 
gene coding for IGF-II was predominant throughout fetal development of the rat 
compared to IGF-I (115, 116). 
The IGF systemimpacts on numerous tissues of the fetus. For example, IGF-I and 
Il stimulated growth, development and differentiation of embryonic rat brainstem and 
skeletal muscle cocultures organotypic of the fetal tongue (117). IGF-I induced a more 
pronounced muscle tissue differentiation while IGF-II induced a more complete neural 
differentiation. IGF-I and Il increased {3H}proline incorporation into type I collagen in 
rat calvarial cultures and decreased collagen degradation as well (118, 119). IGF-II and 
IGFBP-2 mRNA were associated with the proliferation of fetal epiphyseal chondrocytes in 
vitro (120). In rat lung development, IGF-Il was prominent in late fetal life while IGF-I 
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was more prominent postnatally (121). Fetal rat islet cells produced IGF-I and II in vitro 
(122} while exogenous IGF-I and II increased {3H}thymidine incorporation in fetal rat 
islets. IGFBP-1 and 2 and IGF-1 and Il were synergistic in that IGFBP-1 and 2 
potentiated the effect ofIGF-I and Il on increasing DNA synthesis of fetal rat islets. 
The relationship among the IGF's and their binding proteins in the mother and fetus 
In normal rat pregnancies, maternal IGF-1 decreased as gestation progressed (26, 
123) while IGFBP-3 was absent by late gestation. The smaller binding proteins 1 and 2 
persisted during late pregnancy (26, 124). Labeled IGF-I was cleared from the serum of 
pregnant rats approximately five times faster than postpartum rates (125). The rapid 
clearance ofIGF-1 from maternal circulation was associated with the reduction ofIGF 
binding proteins especially IGFBP-3. The decrease in IGFBP-3 was associated with an 
increase in IGFBP-3 protease activity which probably promoted the availability ofIGF-I 
to rapidly growing and differentiating tissues ( 126). 
Fetal plasma from starved rat dams was less potent than fetal plasma from fed rat 
dams in promoting brain cell growth in vitro (127). Analysis of the fetal plasma revealed 
that fetal plasma from starved dams had reduced IGF-I, elevated IGFBP-1 and unchanged 
IGF-II concentrations. The addition ofIGF-I to the starved fetal plasma stimulated brain 
cell growth in vitro while the addition ofIGFBP-1 to fed fetal plasma inhibited brain cell 
growth. However, correcting concentrations ofIGF-1 or IGFBP-1 in starved fetal plasma 
did not completely restore cell growth. Perhaps, reduced glucose concentrations in the 
starved fetal plasma could have contributed to the less than optimal growth response. 
IGF-I concentrations were significantly reduced in small for gestational age (SGA} fetal 
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rats while IGF-II remained unchanged (24, 128). Davenport observed that in the fetus, 
IGF-II and IGF-II mRNA were not affected by maternal fasting (113). Intrauterine 
growth retardation due to maternal fasting was related to decreased IGF-I gene expression 
in the maternal liver and lungs (25, 113) as well as decreased fetal hepatic IGF-I mRNA, 
decreased fetal serum IGF-I concentrations and increased fetal hepatic IGFBP-1 mRNA 
(25). In SGA fetal rats induced by short term (24 hours) uterine artery ligation, fetal 
serum IGF-I was positively correlated with fetal serum insulin, fetal body weight, fetal 
liver weight and fetal brain weight while fetal serum insulin was positively correlated to 
fetal body weight and fetal liver weight but not brain weight (24). Upon further analysis, 
the relationship between IGF-1 and fetal body weight, liver weight and brain weight 
remained significant even when the effect of insulin was controlled for. These data 
indicate that fetal growth retardation due to maternal fasting and uterine arterial ligation is 
related to a decrease in IGF-1 gene expression and an increase in IGFBP-1 gene 
expression which may be related to the metabolic state associated with insulin 
concentrations. It appears that intrauterine growth retardation due to short term nutrient 
restriction is not related to IGF-II gene regulation. 
Effect of diabetes on the IGF's and their binding proteins 
Streptozotocin induced diabetes in nonpregnant rats resulted in discordant organ 
specific regulation ofIGF-1 expression (29). Within the kidney itself, there was a varied 
expression ofIGFBP's as a result of STZ diabetes (129). Kidney weight increased 
dramatically in pre- and postpubertal male SD diabetic rats compared to nondiabetic 
controls (130). The diabetic postpubertal rats had a larger and more significant increase in 
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kidney weight than diabetic prepubertal rats. Plasma IGF-1 concentrations decreased with 
diabetes in both age groups. Renal IGF-1 concentrations increased in both diabetic and 
nondiabetic postpubertal rats but not in the prepubertal rats. Phillip and colleagues also 
observed elevated renal IGF-1 concentrations in 3 month old male SD rats treated with 
STZ despite a decrease in plasma IGF-1 and growth hormone concentrations within 30 
hours of STZ administration (30). In addition, liver and kidney IGFBP-1 mRNA 
concentrations were elevated. In young female SD rats, Luo and Murphy also noted a 
significant increase in renal and hepatic IGFBP-1 mRNA after STZ treatments well as an 
increase in renal and hepatic IGFBP-1 (28). 
In mature male SD rats given varying doses of STZ, hepatic IGF-I mRNA 
decreased in direct proportion to STZ dose while renal IGF-1 mRNA content increased 
inversely proportional to the dose of STZ (29). Bomfeldt et al ( 131) observed a decrease 
in liver IGF-I mRNA 7 days after STZ treatment in 6 - 7 week old male SD rats. IGF-I 
mRNA also decreased in the heart, aorta, kidney and diaphragm compared to non-diabetic 
controls. Growth hormone receptor mRNA concentrations were significantly lower in the 
heart and diaphragm but not the liver or kidney compared to non-diabetic controls. 
Despite diabetes, tibial epiphyseal width and longitudinal tibial bone growth were strongly 
correlated with IGF-1 serum concentrations in young (115 - 125 gram) male Zur:SIV rats 
(27). 
Unterman and colleagues demonstrated that the regulation of the 32kD IGFBP in 
the serum of mature diabetic female SD rats was regulated by insulin (132). This species 
ofIGFBP increased in uncontrolled diabetes and decreased with insulin administration. 
When insulin was withdrawn, the concentrations of the binding protein rose. They 
concluded that IGF-1 binding activity was markedly increased in diabetes due to changes 
in the 32kD IGFBP which in tum was regulated by insulin or the metabolic status 
associated with the presence of absence of insulin. 
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In summary, STZ-induced diabetes resulted th_e differential expression of the IGF 
and IGFBP genes in different tissues. Diabetes decreased hepatic IGF-1 gene expression 
and plasma IGF-1 concentrations. In contrast, diabetes increased renal and hepatic 
IGFBP-1 mRNA and the 32kD IGFBP in serum as well as IGFBP-1 concentrations in the 
tissues and blood. The effect of diabetes on IGF-II per se in non-pregnant animals or the 






To study the effect of chromium and diabetes during pregnancy, this experiment 
utilized a 2x2 factorial arrangement of treatments. The two factors were dietary 
chromium content at low and high levels, and diabetes, induced with an injection of STZ 
in citrate buffer as opposed to an injection with citrate buffer without STZ. Thus, the four 
combinations randomly assigned and applied after pregnancy was confirmed were: 
1) low chromium diet and citrate buffer injection 
2) low chromium diet and STZ in citrate buffer injection 
3) supplemented chromium diet and citrate buffer injection 
4) supplemented chromium diet and STZ in citrate buffer injection. 
Low chromium diets contained 40 µg chromium per kilogram diet (-Cr). Supplemented 
chromium diets contained 2 mg chromium per kilogram diet (+Cr). Diabetes was induced 
with a dose of a 30 milligram per kilogram body weight streptozotocin solubilized in 
citrate buffer (pH 4.5) obtained from Sigma Chemical Co. (St. Louis, MO). The 
following procedures were approved by the Oklahoma State University Animal Care and 
Use Committee. 
Animals and Diets 
Forty female weanling Sprague Dawley rats obtained from Sasco Inc. (Omaha, 
NE) were randomly assigned to one of the four treatments. The rats were individually 
caged in Plexiglas cages with plastic grating for flooring. They were fed a semi-purified 
adaptation diet which contained an average of70 µg chromium/kg diet (Appendix A). 
The rats had free access to the diet and distilled deionized water for drinking. Ceramic 
bowls were used to hold food and water. 
All diet ingredients were analyzed and selected for chromium content before use. 
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Ingredients lowest in chromium were used for the treatment diets (Appendix A). The 
mineral mix for the low chromium diet followed AIN-76 recommendations replacing iron 
citrate with iron chloride, using sodium selenate instead of sodium selenite and did not 
include the addition of chromium potassium sulfate. The mineral mix for the adequate 
chromium diet was made similarly to the low chromium mineral mix with the addition of 
chromium potassium sulfate (Appendix B). Ingredients for the mineral mix were weighed 
then combined and mixed in a burundum-fortified porcelain jar in a roller type mill for 24 
hours. Adaptation (pre-pregnancy) and treatment (pregnancy) diet compositions are 
outlined in Appendix A. The low chromium diets contained 3 9. 7 ± 7. 7 µg chromium/kg 
diet while the adequate chromium diet contained 2.0 ± 0.3 mg chromium/kg diet. 
Diet ingredients were weighed in advance. Vitamin mix was protected from light 
to prevent the breakdown of light sensitive vitamins. In a small mixing bowl (mixture 1), 
dextrose, sucrose, mineral mix, L-cystine and choline bitartrate were blended together 
gently by hand. The oil was added and the mixture mixed in an electric mixer at very low 
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speed for 3 minutes then set aside (mixture 1). In a large institutional size plastic mixing 
bow~ the casein and celufil were gently blended together with a plastic spatula after which 
the vitamin mix was quickly added and blended in. Cornstarch was then added to the 
mixture. The first mixture (mixture 1) in the small mixing bowl was then added very 
carefully to the cornstarch-vitamin mix-celufil-casein mixture to avoid dust formation. 
After making sure that all 10 components of the diet were in the large bowl, the diet was 
then mixed with an institutional size Kitchen Aid mixer for 15 minutes after which the 
sides and bottom of the bowl were scraped to ensure that all of the mixture was mixed 
together well. This was followed by 15 more minutes of machine mixing after which·the 
diets were bagged in plastic bags, marked and stored in the freezer. 
Experimental Protocol 
The rats were bred when they were older than 56 days and weighed more than 150 
grams. Mean breeding age was 126 ± 3 (mean± SEM) days. Mean breeding weight was 
267 ± 8 (mean ± SEM) grams. The heaviest rats were used first. Rats were individually 
penned with one male for breeding. Breeding pairs were checked daily for vaginal plugs 
which confirmed pregnancy. When pregnancy was confirmed, the time was labeled day 1 
of pregnancy. 
On day 1 of pregnancy, the pregnant rat received an injection containing a dose of 
30 mg STZ/k:g body weight solubilized in 0. lM citrate buffer (pH4.5) or an injection 
containing buffer alone via tail vein. From day 1 on, the rat received a low chromium diet 
or an adequate chromium diet. 
A glucose tolerance test was administered on day 18. On day 20, the dams were 
anaesthetized with 130 mg ketamine/kg body weight and 5 mg xylazine/kg body weight. 
The fetuses and placentas were removed by Cesarean-section after which the dams were 
exsanguinated by cardiac puncture. Maternal heart, liver, spleen and kidneys were 
removed and weighed. Fetuses and placentas were counted and individually weighed .. 
Fetuses were quickly decapitated and blood collected with heparinized capillary tubes. 
The fetal blood was pooled in heparinized microcentrifuge tubes. Heparinized blood 
samples were kept on ice until they could be centrifuged, separated and stored at -20°C. 
Maternal plasma was analyzed for glucose, insulin, non-esterified free fatty acids, 
cholesterol, triglycerides, J3-hydroxybutyrate, IGF-I and IGF-II concentrations and IGF 
binding proteins. Fetal plasma was analyzed for glucose, insulin, IGF-I and IGF-II 
concentrations. Proximate analysis was done on maternal liver and fetuses. Fetuses and 
placenta were analyzed for hydroxyproline content. All the tissues collected were 
analyzed for calcium, magnesium, iron, copper and zinc. Chromium and manganese 
concentrations were measured in all the tissues except the spleen because of the large 
amount of concentrated acid needed to solubilize the ashed spleen samples. 
Statistical Analysis 
The GLM procedure of SAS which utilizes the method of least squares to fit 
general linear models was utilized to determine if chromium, diabetes or their interaction 
had a significant effect on the dependent variables analyzed in this study (135). Log 
transformations were performed on variables that were not normally distributed as 
determined by the UNIVARIATE procedure of SAS and are noted in the tables when 




Glucose: Plasma glucose was analyzed by the glucose oxidase method using 
Trinder reagent from Ciba Corning. This spectrophotometric method is based on the 
methodology developed by Trinder (136). The reagent contains glucose oxidase, 
peroxidase, 4-aminoantipyrene and 2,4-dichlorophenol. Glucose oxidase catalyses the 
oxidation of D-glucose in water and in the presence of oxygen to D-gluconic acid and 
peroxide. Peroxidase hydrolyses the peroxide and catalyses the formation of quinonemine 
dye producing a change in color. Color is measured at 505 nm and is directly proportional 
to glucose concentration. 
Insulin: Plasma insulin was determined using the rat radioimmunoassay kit from 
Linco (St. Louis, MO). Following the usual RIA protocol, standards and samples are 
mixed with mI-insulin and insulin antibody then incubated overnight. The next day, a 
precipitating reagent is added. After a short incubation, the tubes are centrifuged then 
decanted. The pellet was counted for radioactivity in a gamma counter and compared 
with standards to determine concentration. In principle, insulin in the sample and the 
radioactive insulin compete for the antibody. The pellet contains bound radioactive 
insulin. Thus, there is an inverse relationship between insulin concentration and 
radioactive binding. 
Blood Lipids: Non-esterified free fatty acid concentrations were determined by the 
method ofMcCutcheon and Bauman (137) using the NEFA-C kit from W AKO Chemicals 
USA Inc. (Dallas, TX). Based on the Trinder principle, this assay measures the color 
change from the formation of quinonemine dye from the reaction of peroxide which is 
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formed from the oxidation of acyl CoA from the fatty acids, 4-aminoantipyrene, 3-methyl-
N-ethyl-N-f3-hydroxyethylaniline and peroxidase. Measured at 550nm on the Beckman 
DU-64 spectrophotometer, the absorbance is directly proportional to the concentration of 
the non-esterified fatty acids. 
Sigma diagnostic kits and reagents (Sigma Chemical Co., St. Louis, MO) were 
used to determine total cholesterol (Catalog No. 352-20), triglyceride (Catalog No. 339-
20) and f3-hydroxybutyrate (Catalog No. 310-A) concentrations. The COBAS FARA II 
automatic analyzer (Roche Diagnostic Systems, NJ) was used to determine f3-
hydroxybutyrate concentrations while cholesterol and triglyceride analysis were performed 
manually. Both cholesterol and triglycerides analytical methods are Trinder based 
methodologies measuring color change from the formation of quinonemine dye as 
discussed in the analysis of glucose and non-esterified free fatty acids. Peroxide is formed 
from the oxidation of cholesterol by cholesterol oxidase and from triglycerides by the 
oxidation of glycerol-I-phosphate from triglycerides by glycerol phosphate oxidase. 
The analysis of f3-hydroxybutyrate depends on the oxidation of the ketone by 3-
hydroxybutyrate dehydrogenase in the presence ofNAD forming acetoacetate, NADH and 
Ir. NADH absorbs light at 340nm so that the increase in absorbance due to the reaction 
is directly proportional to the f3-hydroxybutyrate concentrations in the sample. 
IGF-1 and IGF-11: IGF-1 and -II were extracted from plasma using the formic 
acid-acetone method developed by Bowsher et al (138). IGF-I and IGF-II were 
determined by the RIA method described by Spicer et al (139) and Echternkamp et al 
(140). 
IGF binding proteins: Western ligand blotting was carried out according to the 
method described byEchtemkamp and colleagues (141). Briefly, 4µL of plasma and 
26µL of denaturing buffer were heated then were separated by one dimensional SDS 
PAGE. The binding proteins on the gel were electrophoretically transferred to 
nitrocellulose paper which were then incubated with 1251-IGF-I overnight, washed with 
buffer and exposed to X-ray film for 2 weeks. Band intensities on the radiographs were 
quantified with a PDI Model DNA 35 scanner and the Quantity One (Version 2.4) 
software program for scanning densitometry. 
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Proximate analysis: For moisture and fat analysis, the method described by Firth et 
al (142) was utilized. Frozen maternal liver samples were ground and aliquots weighed 
into dry, labeled, ashless filter paper and clipped. Because of their watery consistency, 
ground fetal aliquots were weighed in special glass tubes with two open ends stopped with 
cotton wool to allow the flow of ether through the sample for fat extraction. The maternal 
liver samples were freeze dried to prevent the evaporation of volatile fatty acids and 
weighed again for moisture determination. Fetal samples were desiccated in a 
conventional drying oven. Fat was extracted from the dried samples in ether extraction 
Soxhlets, dried and re-weighed for the determination of total extractable fat (142). 
Crude protein was determined with a LECO FP-428 (Leco Corp., St. Joseph, MI) 
which is a microprocessor based, software controlled instrument that measures thermal 
conductivity of nitrogen produced by the combustion of the samples (143). Thus, thermal 
conductivity is directly proportional to the amount of nitrogen produced. 
I 
Hydroxyproline: Fetal and placental hydroxyproline were determined using a 
modification of the methods ofBergman and Loxley(l44, 145). Tissue samples were 
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weighed in dried polypropylene tubes of known weight and dried. Dry weights were 
recorded to detennine sample dry weights. Two mL of concentrated hydrochloric acid 
was added to the dry samples and incubated for at least 16 hours at 105°C. The 
hydrolysates werethen neutralized with concentrated LiCl solution using phenolphthalein 
and pH paper to approximate pH. A pH between 4 and 6 was achieved for best results. 
The slightly acid hydrolysates were then brought to a known volume (10 mL for placenta 
and 15 mL for fetus samples). Buffer (Appendix C) and standards of 25, 50 and 100 
µmol/L hydroxyproline were prepared. 
One-halfmL of the samples and standards were pipetted into 12x75mm glass test 
tubes after which 1 mL of2-isopropanol was added. Oxidant solution and Ehrlich's 
reagent were prepared immediately before addition to the samples (Appendix C). One-
half mL of oxidant solution was added to each of the tubes and vortexed. After 4 ± 1 
minutes, 1 mL of Ehrlich's reagent was added and vortexed before incubation in a 
· waterbath set at 60°C for 21 minutes. The tubes were then left at room temperature for 1 
hour before spectrophotometric determination was performed at 562nm. This method 
relies on the formation of pyrrole upon oxidation of the hydroxyproline. The pyrrole then 
forms a chromophore with the p-dimethylaminobenzaldehyde in Ehrlich's reagent (146). 
Mineral Analysis: All necessary precautions were taken to minimize the 
contamination of tissue samples for mineral analysis. Gloves, hair restraints, plastic 
utensils, distilled deionized water and acid washed glassware were used at all times. When 
possible, work was done under a clean air hood. 
Tissue samples were prepared for mineral analysis by a modified procedure 
36 
following the method of Hill et al (147). Samples were weighed into tubes and placed in 
glass beakers covered with Petri dishes and dried for 3 days. After dry tissue weights 
were recorded the samples in their original containers were ashed in a muffle furnace 
ramped at 0.5°C per minute to the ashing temperature of375°C for a duration of24 
hours. The tubes containing the ashed samples were placed in heating blocks and wet 
ashed at 100°C with 50-1 OOµL each of deionized distilled water, double distilled nitric 
acid (G. F. Smith Chemicals, Powell, OH) and 30% hydrogen peroxide (J. T. Baker, 
Phillipsburg, NJ). Hydrogen peroxide was added repeatedly until a clear solution was 
obtained. The tubes were dried in the heating blocks and dry ashed once more in the 
muffle furnace. This cycle of wet ashing and dry ashing was repeated until a soluble, 
colorless and clear solution was obtained. The samples were then analyzed using a Perkin 
Elmer 5100PC atomic absorption spectrophotometer equipped with an air-acetylene flame 
and a graphite furnace with Zeeman background correction for trace mineral analysis. 
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CHAPTER IV 
THE EFFECT OF CHROMIUM AND STREPTOZOTOCIN-INDUCED DIABETES 
ON REPRODUCTIVE PERFORMANCE, CARBOHYDRATE AND LIPID 
METABOLISM AND TRACE ELEMENT INTERACTIONS IN PREGNANCY 
Abstract 
This study was designed to determine the effect of chromium (Cr) depletion and 
diabetes on pregnancy outcome, maternal carbohydrate and lipid metabolism, and the 
distriibution of minerals in maternal tissues, placenta and fetus. Forty weanling female 
Sprague-Dawley rats were randomly assigned to four treatment groups in a 2 x 2 factorial 
design, the factors being the presence or absence of diabetes during pregnancy and 40 µg 
or 2 mg Cr/kg diet given during pregnancy. Treatments were initiated on day 1 of 
pregnancy. Glucose tolerance tests were given on day 18 of pregnancy. All rats were 
necroposied on day 20 for tissue and blood collection. Adequate chromium decreased 
litter size (p<0.05), increased placental weight (p<0.05), and increased concentrations of 
kidney chromium (p<0.0001), heart copper (p<0.05), and kidney zinc (p<0.005). 
Diabetes decreased plasma insulin concentrations (p<O.001 ), increased plasma glucose 
(p<0.01) and fructosamine (p<0.05) concentrations, lowered insulin to glucose ratios 
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(p<0.001), increased blood glucose response to the glucose tolerance test (p<0.05) and 
total plasma triglycerides (p<0.01), enlarged maternal kidneys (p<0.05) and spleens 
(p<0.005), increased fetal resorptions (p<0.01), decreased maternal weight gain (p<0.05), 
litter size (p<0.01) and fetal weight (p<0.05), increased maternal liver and kidney copper 
(p<0.05) and zinc (p<0.01). Significant interaction effects on non-esterified fatty acids 
(p<0.05), maternal liver protein concentrations (p<0.05) and fetal manganese 
concentrations (p<0.05) were observed. Results of the present study confirm that 
chromium and diabetes have an effect on pregnancy outcome and mineral distribution in 
maternal tissues which may be associated with the negative outcomes of pregnancy. 
Introduction 
Four percent of all pregnancies that resulted in live births in 1988 were 
complicated by diabetes (1). Of these 154,000 pregnancies, 88% were complicated by 
gestational diabetes, 8% by non-insulin dependent diabetes and 4% by insulin dependent 
diabetes. Gestational diabetes is diabetes mellitus first diagnosed during pregnancy. Pre-
gestational diabetes is diabetes mellitus that precludes pregnancy. Uncontrolled 
gestational diabetes and pre-gestational diabetes are associated with increased prenatal 
risks such as premature birth, infant morbidity and mortality, congenital abnormalities and 
obstetric complications such as urinary tract infections, polyhydramnios, pre-eclampsia 
and toxemia (2 - 5). Congenital malformations, stillbirth and neonatal death still occur 
despite intensive prenatal care in diabetes (6). 
In late gestation, GDM women have responded to oral glucose challenges with 
higher blood glucose response curves resulting in larger areas under the curve compared 
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to nonnal pregnant women (7). According to the American Diabetes Association (8), 
definitive diagnosis of GDM requires that two or more venous plasma concentrations, 
including fasting values, during a 100 gram oral glucose tolerance test meet or exceed the 
following parameters: fasting, 5.8 mM (105 mg/dL); 1 hour, 10.6 mM (190 mg/dL); 2 
hour, 9.2 mM (165 mg/dL); 3 hour, 8.1 mM (145 ng/dL). 
Maternal nutrition is a significant contributor to the outcome of pregnancy (9). 
Some gestational diabetic women and pre-gestational non-insulin dependent diabetic 
women whose blood sugar concentrations are not controlled by diet therapy alone may 
require supplemental insulin in addition to medical nutrition therapy (9). 
Chromium, which is best known for its insulin potentiating effect and as a 
component of glucose tolerance factor ( 12 - 14 ), may be inadequate in the diets for 
pregnant women. In a preliminary study, chromium supplementation for 8 weeks with 
chromium from chromium picolinate decreased glycosylated hemoglobin, glucose and 
insulin concentrations and improved glucose tolerance in gestational diabetic women (15). 
The analysis of the chromium content of freely chosen and composite institutional diets 
revealed that daily intakes of chromium may be less than the recommended minimum 
estimated safe and adequate daily dietary intake of 50 µg chromium per day (16, 17). 
Maternal chromium status is greatly compromised by the fetus during gestation. 
Aharoni (10) observed a significant decrease in hair chromium between 20 and 32 weeks 
of gestation in nonnal pregnant, gestational and pre-gestational diabetic women. Wallach 
and Verch (11) reported that in rats, the fetoplacental uptake of 51chromium accounted for 
25 to 30% of the 51chromium retained by the mother. 
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Pregnant rats exhibited similar metabolic characteristics as pregnant human beings 
as evidenced by reduced insulin sensitivity in the pregnant rat (18). In the fed state, 
plasma glucose concentrations of pregnant rats were lower than those of virgin controls 
while insulin concentrations as well as insulin to glucose ratios were higher in pregnant 
rats than in virgin controls (19, 20). Plasma triglycerides increased two to threefold 
during pregnancy in women (21, 22) as well as in pregnant rats (23). 
Streptozotocin-induced diabetic pregnant rats gained less weight, were 
hypoinsulinemic, hyperglycemic and had lower insulin to glucose ratios compared to non-
diabetic pregnant controls (24, 25). In women with gestational diabetes mellitus (GDM), 
diurnal blood glucose concentrations were above the concentrations observed in normal 
pregnant women (26). GDM women had higher blood glucose, insulin, free fatty acid and 
P-hydroxybutyrate concentrations than normal pregnant women as well (26). 
Streptozotocin-induced diabetic rat dams had larger placentas and smaller fetuses 
compared to non-diabetic controls (27) as well as a greater incidence of malformations 
(28). In rats, many investigators have reported a significantly smaller number of fetuses 
per litter (27, 29, 30 - 31). Streptozotocin-induced diabetes in pregnancy produced a 
significant increase in total plasma triglycerides (32, 33) and plasma P-hydroxybutyrate 
(33, 34) and a decrease in plasma free fatty acids (33). The rate of protein synthesis in 
diabetic dams and their fetuses was lower than non-diabetic controls while maternal liver 
RNA concentrations decreased and fetal liver RNA concentration increased in the diabetic 
dams at 20 days gestation (3 5). 
In sows, supplemental chromium from chromium picolinate increased gestational 
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weight gain as well as litter size (36). Furthermore, during gestation, insulin response to 
feeding in chromium-supplemented sows is· significantly lower compared to the response 
by unsupplemented sows. A follow-up study by the same group (37), however, did not 
find a significant effect by chromium on litter size but the chromium-treated group did 
have an average of one more live birth than the controls. The effect of supplemental 
chromium on litter size in rodents has not been evaluated. 
Diabetes mellitus in pregnancy resulted in abnormal micronutrient status (27, 34, 
38 - 40). Gestational diabetic women had lower erythrocyte intracellular free magnesium 
compared to normal pregnant controls and non-pregnant women ( 41 ). Gestational 
diabetic women had lower hair chromiuin content compared to normal pregnant women 
(10). Diabetic pregnant rats had higher kidney and liver manganese, zinc and copper while 
their fetuses had low concentrations of liver zinc and high concentrations of liver 
inanganese (27, 28). Placental calcium, magnesium and iron are reduced in diabetic 
pregnant rats in these same studies compared to the fetuses of non-diabetic dams (27). It 
is not known whether dietary chromium depletion exacerbates glucose intolerance in 
diabetic pregnancies and whether this affects the distribution of minerals in maternal 
tissues or the fetus. The objective of this study was to determine the effects of chromium 
depletion and STZ-induced diabetes on maternal carbohydrate and lipid metabolism, 
pregnancy outcome, organ hypertrophy and the distribution of minerals in the tissues of 
rats during pregnancy. 
Research Design and Methods 
Forty female weanling Sprague Dawley rats, obtained from Sasco Inc. (Omaha, 
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NE), were randomly assigned to one of the four treatments in a 2 x 2 factorial design. The 
four treatments were: 1) low chromium diet (40 µg Cr/kg diet), citrate buffer injection, 2) 
. low chromium diet, STZ (30 mg STZ/kg body weight) in citrate buffer injection, 3) 
adequate chromium diet (2 mg Cr/kg diet), citrate buffer injection, and 4) adequate 
chromium diet, STZ in citrate buffer injection. The rats were individually caged in 
Plexiglas cages with plastic grating for flooring. The rats were fed an adaptation diet 
which contained an average of 70 µg Cr/kg diet. The rats had free access to the diet and 
distilled deionized drinking water. Ceramic bowls were used to hold food and water. 
Adaptation and treatment diet compositions are outlined in Table IV. l. The low 
chromium diets contained 39.7 ± 7.7 µg chromium/kg diet while the adequate chromium 
diet contained 2.0 ± 0.3 mg Cr/kg diet. 
Mean breeding age was 126 ± 3 (mean± SEM) days. Mean breeding weight was 
267 ± 8 (mean± SEM) grams. The heaviest rats were used first. Rats were individually 
penned with one male for breeding. Breeding pairs were checked daily for vaginal plugs. 
For each rat, the day that a vaginal plug was found was labeled day 1 of pregnancy. 
On day 1 of pregnancy, each pregnant rat received an injection via tail vein 
containing either a dose of30 mg STZ/kg body weight solubilized in O. lM citrate buffer 
(pH 4.5) or citrate buffer alone. The STZ and citrate buffer were mixed immediately 
before the injection. From day 1 on, each rat received a low chromium diet ( 40 µg/kg 
diet) or an adequate chromium diet (2 mg/kg diet) until termination of the experiment. 
A glucose tolerance test {lg glucose/kg body weight) was administered on day 
18. On day 20, the dams were anesthetized with 130 mg ketamine/kg body weight and 5 
mg xylazine/kg body weight. The fetuses and placentas were removed by Cesarean 
section after which the dams were exsanguinated by cardiac puncture. Fetuses and 
placentas were counted and individually weighed. Heparinized blood samples were kept 
on ice untill thery were centrifuged, and plasma separated and stored at -20°C. 
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Maternal plasma was analyzed for glucose, fructosamine, insulin, non-esterified 
free fatty acids, cholesterol, triglycerides and P-hydroxybutyrate in day 20 samples. 
Plasma glucose was analyzed by the glucose oxidase method using Trinder reagent from 
Ciba Coming (Oberlin, OH). Plasma fructosamine was determined by the ROT AG 
method with the COBAS FARA TI clinical analyzer (Roche Diagnostic Systems, 
Branchburg, NJ). Plasma insulin was determined using the radioimmunoassay kit from 
Linco (St. Louis, MO). Non-esterified free fatty acid concentrations were determined by 
the method of McCutcheon and Bauman ( 42) using the NEF A-C kit from W AKO 
Chemicals USA Inc. (Dallas, TX). Sigma diagnostic kits (Sigma Chemical Co., St. Louis, 
MO) and reagents were used to determine total cholesterol (Catalog No. 352-20), 
triglycerides (Catalog No. 339-20) and P-hydroxybutyrate (Catalog No. 310-A) 
concentrations. Samples for P-hydroxybutyrate analysis were deproteinized by the 
method ofMellanby and Williamson (43) and analyzed with a COBAS FARA II clinical 
analyzer (Roche Diagnostic Systems, Branchburg, NJ) using the protocol provided by 
Sigma. 
To evaluate glucose tolerance, the area under the glucose tolerance curve (AUC) 
was calculated by adding the areas under each pair of consecutive blood glucose 
observations using the formula: · 
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(44) 
where t = time in minutes and y = blood glucose concentration expressed as mmol/L. The 
area under the curve will be expressed as GTTAUC units in the text and table. 
Maternal liver moisture and fat content were determined following the procedure 
described by Firth and colleagues ( 45) utilizing the ether soxhlet extraction method of 
freeze dried animal tissue. Protein was analyzed using a LECO FP-428 which measures 
the thermal conductivity of nitrogen gas produced upon combustion of the sample (46). 
Tissue samples were weighed into acid-washed borosilicate tubes and dried at 
100°C for 24 hours. Dry weights were recorded after which the samples were ashed in a 
muffle furnace (Lindberg, Watertown, WI). The tubes were then placed in heating blocks 
which were enclosed in a well ventilated hood and the samples wet-ashed using 
concentrated nitric acid and 30% hydrogen peroxide as previously described by Hill et al 
(47). Samples were dried on the heating blocks after which they were ashed in the muffle 
furnace. The wet ashing-dry ashing procedure was repeated until the remaining sample 
was soluble and clear in solution. The samples were analyzed for calcium, magnesium, 
copper, iron, zinc, chromium. and manganese using a Perkin Elmer Model 51 OOPC atomic 
absorption spectrophotometer with an acetylene flame and a graphite furnace with Zeeman 
background correction (Perkin Elmer, Norwalk, CT). 
Statistical analysis was performed using the GLM procedure of SAS (1985) to 
determine factorial effects and their interactions. Log transformations were used to 
normalize variables exhibiting heterogenous variance which was determined by the 
Shapiro-Wilk test for normality utilized by the SAS procedure UNIVARIATE (48). 
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Analyses of variance using transformed variables have been indicated in the tables. Data in 
this study are presented as mean ± standard error of the mean. 
Results 
Carbohydrate metabolism. Plasma insulin was lower (p<0.001) in the diabetic 
(0.10 ± 0.02 pmol/L, Table IV.2) than in the non-diabetic group {0.40 ± 0.08 pmol/L). In 
contrast, glucose concentrations were elevated (p<0.01) in the diabetic group (27.42 ± 
3.01 mmol/L) compared to the non-diabetic group (17.96 ± 0.93 mmol/L). Serum 
fructosamine concentrations which were significantly greater (p<0.05) in the diabetic 
group confirm that the diabetic group was hyperglycemic during the last half of pregnancy. 
Mean plasma fructosamine for the diabetic group was 388.1 ± 35.2 µmol/L while the 
mean for the non-diabetic group was 262.9 ± 39.3 µmol/L. The insulin to glucose ratio 
was lower (p<0.0001) in the diabetic group compared to the non-diabetic group. Glucose 
tolerance curves are illlustrated in Fig. IV.1. Glucose concentrations were greater 
(p<0.05) in the diabetic group than in the non-diabetic group before glucose loading as 
well as after glucose was given. The area under the curve (TableIV.2) was significantly 
greater (p<0.05) in the diabetic group (3.31 ± 0.84 GTTAUC units) than in the non-
diabetic group {1.04 ± 0.03 GTTAUC units). Chromium did not have an effect on plasma 
glucose, fructosamine, insulin, insulin to glucose ratio or glucose tolerance. 
Blood lipids and lipid metabolites. Plasma cholesterol and ~-hydroxybutyrate 
concentrations were similar among the groups. Mean total plasma cholesterol was 2.45 ± 
0.31 mmol/L and mean ~-hydroxybutyrate concentration was 307 ± 95 µmol/L. Plasma 
total triglyceride concentrations were higher in the diabetic group (p<0.01) than the non-
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diabetic group. Mean plasma total triglyceride concentration for the diabetic group was 
6.17 ± 0.97 mmol/L while the non-diabetic group had a mean concentration of3.02 ± 0.38 
mmol/L. A significant interaction effect on plasma non-esterified fatty acids (p<0.05) was 
observed such that plasma concentration within the diabetic group increased with 
adequate chromium diets. 
Outcome of pregnancy. Body weights at breeding and at day 20 of pregnancy as 
well as the number of ovulations were not different among treatment groups (Table IV.4). 
However, diabetes decreased (p<0.05) maternal weight gain and chromium had a tendency 
(p<O .1) to decrease weight gain as well. Mean weight gain for the diabetic group was 71 
± 11 grams compared to 101 ± 6 grams for the non-diabetic group. Mean weight gain for 
the adequate chromium group was 76 ± 8 grams and 96 ± 8 grams for the chromium 
depleted group. 
Both chromium and diabetes had significant negative effects on litter size. The 
average number of viable fetuses per dam in the adequate chromium group was 9 ± 1 
fetuses per litter compared to 11 ± 1 fetuses per litter in the chromium depleted group 
(p<0.05). Mean litter size for the diabetic group was 8 ± 1 fetuses per litter compared to 
12 ± 1 fetuses per litter in the non-diabetic group (p<0.01). In addition, the diabetic group 
had a larger number of resorptions (7 ± 1) than the non-diabetic group (3 ± 1, p<0.01). 
Diabetes also had a negative effect (p<0.05) on mean fetal weight. Average fetal weight 
at day 20 for the diabetic group was 3.5 ± 0.2 grams in contrast to an average of 4.1 ± 0.1 
grams per fetus in the non-diabetic group. 
Tissue weights. The diabetic dams had larger kidneys (p<0.05) than the non-
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diabetic dams (Table IV.5). Mean kidney weight of the diabetic dams was 2.33 ± 0.18 
grams compared to 1.82 ± 0.10 grams for the non-diabetic dams. When expressed as 
percent bodyweight, spleens of the diabetic dams were larger (p<0.005) than the non-
diabetic dams. Average spleen weight in the diabetic group was 0.71 ± 0.02 grams (0.22 
± 0.01 % body weight) compared to 0.64 ± 0.03 grams (0.18 ± 0.01 % body weight) in 
the non-diabetic group. Liver weights and lung weights expressed as percent body weight 
had a tendency to be larger in the diabetic dams (p<O. l). Placentas, when expressed as 
percent body weight, from the adequate chromium dams were larger (0.15 ± 0.01 %, 
p<0.05) than those from the chromium depleted dams (0.13 ± 0.01 %). 
Liver proximate analysis. Liver moisture and fat content were not significantly 
different among treatment groups. Mean moisture content was 70 ± 2 % and mean 
extractable fat was 5 ± 2 %. A significant interaction effect on liver protein content was 
observed such that within the chromium depleted group diabetic rats had greater liver 
protein concentrations than the non-diabetic rats. 
Chromium (Cr). The adequate chromium group had greater (p<0.0001) chromium 
concentrations in the kidneys than the chromium depleted group (Table IV. 7). Mean 
kidney chromium concentration for the adequate chromium group was 1.53 ± 0.23 µmol 
Cr/kg dry tissue compared to a mean of 0.35 ± 0.16 µmol Cr/kg dry tissue in the 
chromium depleted group. A significant interaction effect on concentrations of chromium 
in the heart was observed such that within the adequate chromium group, diabetes 
decreased (p<0.05) heart chromium concentration but did not exhibit the same effect in 
the chromium depleted group. 
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Manganese (Mn). Mean kidney manganese concentration was greater (p<0.05) in 
the chromium depleted group (76.38 ± 2.34 µmol Mn/kg tissue) than in the adequate 
chromium group (70.69 ± 1.75 µmol Mn/kg tissue, Table IV.8). A significant interaction 
effect was observed such that within the diabetic group, rats fed adequate chromium diets 
had lower (p<0.05) fetal manganese concentrations than the chromium depleted group 
while in the non-diabetic group, chromium did not exhibit the same effect. 
Copper (Cu). The diabetic dams had elevated liver (p<0.05) and kidney 
(p<0.0005) copper concentrations compared to the non-diabetic dams (Table IV.9). 
Mean liver copper for the non-diabetic group was 0.168 ± 0.005 mmol Cu/kg tissue while 
mean concentration for the diabetic group was 0.224 ± 0.022 mmol Cu/kg tissue. Mean 
kidney copper concentration for the non-diabetic group was 0.35 ± 0.03 mmol Cu/kg 
tissue in contrast to 1.41 ± 0.25 mmol Cu/kg tissue. Mean heart.copper concentration for 
the adequate chromium group was greater (p<0.05) in the adequate chromium group 
(0.325 ± 0.004 mmol Cu/kg tissue) than in the chromium depleted group (0.308 ± 0.007 
mmol Cu/kg tissue). There was a tendency (p<O .1) for diabetes to increase heart copper 
concentrations and for a treatment interaction effect on heart copper concentrations. 
Zinc (Zn). Mean liver zinc concentration was greater (p<0.01) in the diabetic 
group ( 1. 77 ± 0 .11 mmol Zn/kg tissue) than in the non-diabetic group ( 1. 44 ± 0. 03 mmol 
Zn/kg tissue). Mean kidney zinc concentration was also higher (p<0.005) in the diabetic 
group (1.87 ± 0.07 mmol Zn/kg tissue) than in the non-diabetic group (1.62 ± 0.05 mmol 
Zn/kg tissue). Kidney zinc concentrations were also greater (p<0.05) in the adequate 
chromium group (1.82 ± 0.06 mmol Zn/kg tissue) than in the chromium depleted group 
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(1.67 ± 0.08 mmol Zn/kg tissue). 
Iron. Tissue iron concentrations were not significantly different among groups but 
there was a tendency for spleen iron concentrations to be lower and fetal iron 
concentrations to be elevated in the diabetic group (Table IV .11). 
Calcium and magnesium. There were no significant differences in tissue calcium 
and magnesium concentrations among the groups but there was tendency for spleen 
calcium and liver magnesium to be greater in the adequate chromium group (Tables IV.12 
and IV.13). 
Discussion 
In agreement with the literature (24, 27 - 28), we observed that diabetic dams had 
decreased plasma insulin concentrations and increased plasma glucose concentrations 
resulting in lower insulin to glucose ratios. We also observed that diabetic dams 
responded to the oral glucose tolerance test with higher plasma glucose concentrations 
resulting in a larger area under the glucose response curve which indicates severe glucose 
intolerance. 
Evidently uncontrolled insulin dependent diabetes as seen in our model has adverse 
effects on the outcome of pregnancy. In the present study, the diabetic dams gained less 
weight, had a greater number of fetal resorptions, smaller fetuses and a smaller litter size. 
Other investigators have reported similar :findings (27, 30-34). 
The diabetic dams in the present study had elevated plasma triglyceride 
concentrations but not elevated f3-hydroxybutyrate concentrations as has been observed 
previously (32, 33). Beta-hydroxybutyrate is one of the end products of the f3-oxidation 
of fatty acids in the liver. Diabetic keto-acidosis occurs when ketone bodies such as P-
hydroxybutyrate accumulate in the body. 
50 
Insulin is a potent inhibitor of adipose tissue lipolysis by hormone sensitive lipase 
(50, 51) and, consequently, the release ofNEFA's into the circulation. Thus, elevated 
concentrations ofNEFA's are expected with low concentrations of insulin (50). 
However, decreased concentrations of plasma NEF A's have been observed in diabetic 
pregnant rats not treated with insulin (33). In this study, diabetes increased NEFA 
concentrations in the group of rats receiving adequate chromium in their diet but did not 
have the same effect in the chromium depleted group. The interaction of dietary 
chromium and diabetes in this respect suggests that dietary chromium may increase tissue 
lipolysis in uncontrolled diabetes when insulin is inadequate perhaps by increasing 
hormone sensitive lipase activity. Chromium depletion on the other hand may decrease 
hormone sensitive lipase activity. Further investigation is warranted to determine if 
chromium modulates hormone sensitive lipase activity in adipose tissue and whether this 
response is different between pregnant or non-pregnant animals with or without diabetes. 
Chromium in the present study had a negative effect on litter size and did not 
affect maternal glucose tolerance. There are several possible reasons our results differ 
from Lindemann's sow study (37). Aside from species differences, the sows were fed 
chromium supplemented diets during growth and throughout pregnancy and lactation at a 
level of200 µgadded Cr per day from CrPic. Total dietary chromium concentrations 
were not specified. In the present study, the virgin rats were maintained on the adaptation 
diet containing 70 µg Cr/ kg diet during their growth phase and until pregnancy was 
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confirmed. This was followed by diets containing 2 mg Cr/ kg diet from chromium 
potassium sulfate over the 20 day gestation period. Thus, the timing and amount of 
chromium in the diet may account for the differences in our results. The dietary source of 
chromium may have affected outcomes as well. Although, different sources of chromium 
in the diet have been shown to affect the incorporation of chromium into various tissues in 
weanling Wistar rats (53), results from a preliminary study by Ward and colleagues (52) 
indicated that different sources of dietary chromium did not differ in their effect on 
growth, plasma metabolites, insulin and growth hormone in growing, :finishing swine. In 
retrospect, it is possible that the chromium depleted rats ate more to compensate for the 
inadequate chromium in the diet resulting in increased maternal weight gain and increased 
litter size. Unfortunately, food intake in this study was not measured. 
Interaction effects on maternal liver protein concentrations were such that diabetes 
increased maternal liver protein concentrations in the chromium depleted rats but not in 
the diabetic rats receiving adequate chromium in their diet. In contrast, Martin and 
coworkers (3 5) noted a decrease in maternal liver RNA and rate of protein synthesis in 
diabetic versus non-diabetic control rats at 20 days of gestation. It seems that the 
presence of chromium in the diet of the diabetic dams prevented the negative effect of 
diabetes on liver protein concentrations. Chromium's effect on liver function and 
morphology may be worthy of further study to determine if adequate chromium in the diet 
during diabetes maintains liver integrity. 
Previously reported effects of diabetes on renal hypertrophy and the accumulation 
of zinc and copper in maternal kidneys and liver were confirmed in the present study. 
Similar outcomes occurred in pregnant and non-pregnant spontaneously diabetic BB 
Wistar rats (34, 54). Hyperzincuria has been observed in diabetic human subjects (55) 
accompanied by low levels of plasma zinc indicative of compromised zinc status in 
diabetes. Maternal zinc deficiency is associated with a greater incidence of fetal 
malformations in STZ-induced diabetic rats (39). Perhaps, abnormal zinc status 
contributed to the adverse outcome of pregnancy in diabetes. 
In the present study, chromium depletion increased kidney manganese while 
diabetes had no effect. Some studies demonstrated that diabetes increased kidney 
manganese concentrations in pregnancy (27 - 28) while one study (39) reported no 
differences in kidney manganese concentrations between diabetic and non-diabetic 
pregnant rats. 
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Copper, zinc and manganese are components of and associated with the 
antioxidant property of superoxide dismutase (SOD) (56). In previous studies, manganese 
superoxide dismutase (MnSOD) and ZnCuSOD activities in the kidneys decreased with 
manganese deficiency and were exacerbated by diabetes (57, 58). Whether renal 
superoxide dismutase activity is affected by chromium depletion and diabetes requires 
further investigation. In addition, the effect of chromium depletion on kidney function and 
histology should be elucidated. 
Fetal liver manganese has been observed to increase with diabetes (27 - 28). In the 
present study, an interaction effect on total fetal manganese was observed. Total fetal 
manganese concentrations increased with diabetes in the chromium depleted group while 
in the adequate chromium group, diabetes caused a slight decrease in fetal manganese 
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concentrations. If the increase in fetal manganese concentrations as a result of diabetes is 
associated with the adverse outcome of diabetic rat pregnancies, then the interaction of 
chromium and diabetes on fetal manganese seems to suggest that chromium opposes the 
effect of diabetes on the fetus. This warrants further investigation. 
In conclusion, in addition to the adverse effects of diabetes on maternal 
metabolism and the outcome of pregnancy, diabetes also had an effect on tissue mineral 
distribution, particularly zinc and copper which have antioxidant properties in conjunction 
with superoxide dismutase. Chromium deficiency also had an effect on the distribution of 
minerals in the tissues as well as an interactive effect with diabetes on fetal manganese 
concentrations which may have been related to litter size. Whether this response is the 
organism's way of coping with the oxidative stress of diabetes and with chromium 
deficiency during pregnancy needs to be determined. Further research is needed to 
determine if physiological functions are affected by the redistribution of zinc and copper in 
the liver and kidneys as well as manganese in the maternal kidneys and fetuses under the 
stress of diabetes or dietary chromium manipulation associated with negative outcomes 
and to determine the mechanisms by which these responses occur during pregnancy in the 
rat. 
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Composition of the adaptation and treatment diets used for this study 
Components: Adaptation diet: Treatment diet: 
(g/kg diet) (g/kg diet) 
Cornstarch* 430 150 
Casein* 200 200 
Dextrose* 100 O 
Sucrose 100 500 
Soybean oil 70 50 
Celufil* 50 50 
AIN-76 mineral mixt 35 35 
AIN76A vitamin mix:j: 10 10 
L-Cystine 3 3 
Choline bitartrate 2 2 
* Harlan Teklad (Madison, WI) 
t Prepared in our laboratory. Mineral mix for the treatment diets contained iron chloride 
instead of iron citrate. The mineral mix for the low chromium diet did not include the 
addition of chromium potassium sulfate. 
:j: USB (Cleveland, OH) 
62 
Table IV.2 
Plasma glucose, insulin, insulin:glucose ratio and glucose tolerance test area under the 
curve (GTTAUC) of normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)*. 
Group Insulin Glucose Insulin: 
pmol/L mmol/L glucose ratio 
-Cr-STZ 0.54 ± 0.15 19 ± 1 0.030 ± 0.009 
n=8 n=9 n=8 
-Cr+STZ 0.12 ± 0.03 26±3 0.005 ± 0.002 
n=9 n=lO n=9 
+Cr-STZ 0.30 ± 0.08 17 ± 1 0.020 ± 0.005 
n=lO n=lO n=lO 
+Cr+STZ 0.07 ± 0.02 29±5 0.004 ± 0.001 
n=8 n=9 n=8 













1.12 ± 0.03 
n=3 
3.81 ± 1.30 
n=5 
0.99 ± 0.03 
n=5 

























Total plasma cholesterol, triglycerides, non-esteri:fied free fatty acid (NEF A) and ~-
hydroxybutyrate concentrations of normal and STZ-induced diabetic dams fed diets with 



















* Mean± SEM 
2.19 ± 0.18 3.49 ± 0.65 1.50 ± 0.18 344 ± 54 
n=8 n=9 n=9 n=5 
2.88 ± 0.49 5.62 ± 1.48 1.34 ± 0.23 282 ± 30 
n=lO n=7 n=8 n=8 
2.24 ± 0.18 2.55 ± 0.36 1.13 ± 0.02 315 ± 30 
n=9 n=9 n=7 n=8 
2.41 ± 0.13 6.60 ± 1.35 1.82 ± 0.20 295 ± 45 
n=8 n=9 n=8 n=6 
Analysis of variance 














Pregnancy outcome of normal and STZ-induced diabetic dams fed diets with or without added chromium (Cr)* 
Outcome parameters: .................................. Experimental Groups ............. ......................... P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx STZ 
Weight at breeding (g) 271 ± 14 279 ± 17 253 ± 19 267 ± 18 0.3820 0.5237 0.8404 
n=lO n=lO n=lO n=lO 
Weight at day 20 (g) 382 ± 17 338 ± 21 342 ± 28 313 ±25 0.1839 0.1351 0.7623 
n=lO n=7 n=lO n=8 
Weight gain (g)t 111 ± 5 80 ± 15 90± 10 61 ± 16 0.0946 0.0161 0.9202 
n=lO n=7 n=lO n=8 
Ovulations (n) 16 ± 1 16 ± 1 14 ± 1 16 ± 1 0.2069 0.5953 0.1599 
n=lO n=lO n=9 n=lO 
Viable fetuses/litter (n) 13 ± 1 9±2 10 ± 1 7±1 0.0290 0.0067 0.5239 
n=lO n=lO n=lO n=lO 
Resorptions (n) 3±1 6±2 4±1 8±1 0.3924 0.0091 0.5851 
n=lO n=lO n=9 n=lO 
Mean pup weight (g) 4.2±0.2 3.3 ± 0.4 4.0 ± 0.1 3.6 ±0.2 0.8328 0.0145 0.3562 
n=lO n=lO n=lO n=lO 
* Mean±SEM 
t Weight gain between breeding and day 20 of gestation 
~ 
Table IV.5 
Weights and percent bodyweight of various tissues from normal and STZ-induced diabetic dams fed diets with or without added 
chromium (Cr)* 
Tissue weight {g) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Treatment Groups ................. ................... P value ................... 
{% bodyweight} -Cr-STZ -Cr+STZ +Cr-STZ +cr+STZ Cr STZ CrxSTZ 
Liver 13.5 ± 1.2 12.9 ± 0.66 12.4 ± 1.2 13.4± 1.0 0.7927 0.8603 0.4730 
(3.5 ± 0.2) (3.8 ± 0.12) (3.6±0.1) (4.1 ± 0.2) (0.2828) (0.0641) (0.5501) 
n=lO n=lO n=lO n=lO 
Kidney 1.9 ± 0.1 2.3 ± 0.25 1.7 ± 0.2 2.3 ± 0.3 0.6979 0.0183 0.6560 
(0.50 ± 0.01) (0.60 ± 0.06) (0.50 ± 0.02) (0.73 ± 0.1) (0.2984) (0.0193) (0.3476) 
n=lO n=lO n=lO n=lO 
Spleen 0.64 ± 0.04 0.72 ± 0.03 0.64 ±0.04 0.70 ± 0.03 0.9017 0.0627 0.7944 
(0.17 ± 0.01) (0.22 ± 0.01) (0.19 ± 0.01) (0.22 ± 0.02) (0.2080) (0.0011) (0.4200) 
n=lO n=IO n=IO n=IO 
Heart 0.86 ±0.04 0.86 ± 0.04 0.82 ± 0.05 0.84 ±0.06 0.5514 0.8854 0.8369 
(0.23 ± 0.01) (0.25 ± 0.01) (0.24 ± 0.01) (0.26 ± 0.01) (0.2017) (0.1671) (0.8454) 
n=lO n=lO n=IO n=IO 
Lung 1.23± 0.06 1.23 ± 0.08 1.16±0.05 1.23 ± 0.05 0.6063 0.6063 0.5629 
(0.33 ± 0.02) (0.37 ± 0.03) (0.35 ± 0.01) (0.40 ± 0.03) (0.2811) (0.0552) (0.9281) 
n=IO n=lO n=lO n=lO 
Placenta 0.45 ± 0.01 0.51 ± 0.03 0.48 ± 0.02 0.51 ± 0.03 0.6034 0.1267 0.5315 
(0.12 ± 0.005) (0.15 ± 0.01) (0.15 ± 0.01) (0.16 ± 0.01) (0.0422) (0.0812) (0.5482) 





Liver moisture, fat and protein concentration of normal and STZ-induced diabetic dams fed 
diets with or without added chromium (Cr)* 
Group Moisture Fat Protein 
(%) (%) (%) 
-Cr-STZ 70±2 5±2 18.5 ± 1.7 
-Cr+STZ 69±2 5±2 20.6 ± 1.3 
+Cr-STZ 70±2 5±2 19.7 ± 1.3 
+Cr+STZ 70±3 6±4 19.4±1.1 


















Chromium concentration (µmoVkg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Tissue: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Treatment Groups ................ . ................... P value .................. . 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Cr x STZ 
Kidney 0.0±0 0.59 ± 0.24 1.67 ±0.28 1.44 ± 0.33 0.0001 0.5071 0.1501 
n=7 n=lO n=6 n=lO 
Heart 0.22 ± 0.05 0.30 ±0.08 0.57 ±0.14 0.21 ± 0.06 0.1477 0.1151 0.0198 
n=lO n=8 n=9 n=9 
Fetus 0.13± 0.05 0.03 ± 0.01 0.12 ±0.05 0.07 ±0.03 0.7211 0.0977 0.5518 
n=9 n=8 n=9 n=8 
Placenta 0.49 ± 0.12 0.53 ± 0.18 0.56 ± 0.16 0.62 ± 0.21 0.6559 0.7610 0.9599 
n=9 n=6 n=7 n=8 
*Mean±SEM 




Manganese concentration (µmol/kg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or 
without added chromium (Cr)* 
Tissue: .................................. Experimental Groups ............. . .................. P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx STZ 
Liver 54.25±7.17 42.66 ± 1.53 41.10 ± 1.57 44.86±4.00 0.1960 0.3522 0.0736 
n=9 n=IO n=9 n=9 
Kidney 77.04 ± 4.51 75.80 ± 2.19 73.40 ± 2.12 65.26 ±0.94 0.0263 0.1320 0.2631 
n=8 n=9 n=IO n=5 
Heart 40.01 ± 2.12 33.34 ± 3.46 34.46 ± 3.86 34.33 ± 2.71 0.4849 0.3000 0.3187 
n=8 n=9 n=lO n=9 
Fetus 34.29 ± 0.77 42.05 ± 4.04 36.57 ± 1.49 32.73 ± 1.39 0.1194 0.3786 0.0129 
n=lO n=8 n=9 n=7 
Placenta 15.52 ± 1.60 12.99 ± 1.93 14.68 ± 2.71 13.75±1.14 0.9840 0.3692 0.6781 
n=IO n=6 n=7 n=8 
* Mean± SEM 
°' 00 
Table IV.9 
Copper concentration (mmol/kg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Tissue: .. . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . Treatment Groups ................. ................... P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx STZ 
Liver 0.16 ±0.01 0.24 ±0.03 0.17±0.01 0.21 ± 0.03 0.6990 0.0183 0.3546 
n=9 n=IO n=IO n=9 
Kidney 0.33 ± 0.05 1.10 ± 0.22 0.39 ± 0.02 1.72 ± 0.44 0.1537 0.0001 0.2389 
n=9 n=7 n=7 n=7 
Spleen 0.11 ± 0.01 0.11 ± 0.01 0.11 ± 0.01 0.10 ± 0.01 0.7327 0.2645 0.1847 
n=6 n=6 n=IO n=5 
Heart 0.29 ± 0.01 0.32 ± 0.01 0.324 ± 0.003 0.32 ± 0.01 0.0411 0.0622 0.0990 
n=lO n=9 n=IO n=IO 
Fetus 0.21 ± 0.01 0.21 ± 0.02 0.22 ± 0.01 0.18 ± 0.02 0.3405 0.3003 0.1348 
n=IO n=8 n=9 n=8 
Placenta 0.27 ± 0.03 0.23 ± 0.03 0.24 ± 0.01 0.20 ± 0.03 0.2737 0.1960 0.9991 





Zinc concentration (mmol/kg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Tissue: ................ , ................. Experimental Groups ............. . .................. P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +cr+STZ Cr STZ Crx STZ 
Liver 1.41 ± 0.06 1.63 ± 0.11 1.48 ±0.04 1.90 ± 0.18 0.1515 0.0076 0.3808 
n=9 n=IO n=IO n=IO 
Kidney 1.48 ± 0.05 1.81 ± 0.11 1.71 ± 0.06 1.93 ±0.10 0.0342t 0.0032t 0.4135t 
n=7 n=IO n=IO n=IO 
Spleen 1.36 ±0.08 1.25 ± 0.02 1.37 ± 0.07 1.27 ± 0.07 0.7996 0.1721 0.9459 
n=6 n=6 n=IO n=5 
Heart 0.89 ±0.03 0.90 ±0.02 0.95 ± 0.03 0.92 ±0.02 0.1227 0.7555 0.3465 
n=IO n=9 n=IO n=IO 
Fetus 1.96 ± 0.03 2.00 ±0.03 1.99 ± 0.07 1.96 ± 0.08 0.9170 0.8828 0.5140 
n=9 n=8 n=9 n=8 
Placenta 1.08 ± 0.04 1.04 ± 0.03 1.05 ± 0.03 1.03 ± 0.02 0.5268 0.3692 0.8496 
n=IO n=6 n=7 n=8 
*Mean±SEM 
tResults from analysis of log transformed data 
...J 
0 
Table IV.I I 
Iron concentration (mmol/kg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Tissue: .. .. . . .. .. .. .. .. .. .. .. . .. .. .. .. .. . Treatment Groups ................. ................... P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx STZ 
Liver 7.72 ± 1.64 7.84 ± 1.17 7.73 ±0.96 8.33 ± 1.47 0.8501 0.7857 0.8567 
n=9 n=IO n=IO n=IO 
Kidney 4.52 ± 0.44 4.33 ± 0.48 4.42 ±0.24 4.11 ± 0.36 0.7021 0.5623 0.8869 
n=9 n=lO n=7 n=8 
Spleen 59.78 ± 19.00 36.40 ± 5.92 59.09 ± 9.86 38.48 ± 11.87 0.9567 0.0968 0.9143 
n=IO n=6 n=IO n=5 
Heart 3.26 ± 0.05 3.19±0.12 3.19±0.05 3.30 ± 0.09 0.8538 0.8129 0.2991 
n=IO n=9 n=9 n=IO 
Fetus 3.40 ± 0.26 4.46 ± 0.52 3.66 ± 0.26 3.86 ± 0.27 0.6173 0.0703 0.2129 
n=lO n=8 n=9 n=8 
Placenta 9.97 ± 0.36 10.17 ± 0.80 10.01 ± 0.91 10.72 ± 0.99 0.6958 0.5489 0.7358 




Calcium concentration (mmol/k:g dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Tissue: .. .. .. . .. .. .. .. .. .. .. .. .. .. . .. .. .. Treatment Groups ................. ................... P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx 
STZ 
Liver 1.80 ± 0.06 1.93 ± 0.11 1.92 ± 0.10 1.96 ± 0.06 0.3950 0.3750 0.6029 
n=9 n=IO n=9 n=9 
Kidney 274.97 ± 80.72 317.13 ±88.22 174.32 ± 45.51 300.76 ± 50.74 0.3768 0.2063 0.5231 
n=7 n=7 n=IO n=8 
Spleen 3.14 ± 0.21 2.69 ±0.06 3.32 ± 0.19 3.21 ± 0.18 0.0774 0.1509 0.3796 
n=6 n=6 n=IO n=5 
Heart 3.14±0.12 3.46 ± 0.19 3.45 ± 0.16 3.27 ±0.11 0.6929 0.6519 0.0970 
n=IO n=9 n=9 n=IO 
Fetus 390.59 ± 11.49 379.86 ± 17.58 391.83 ± 6.85 362.96 ± 12.72 0.5424 0.1299 0.4813 
n=9 n=8 n=8 n=8 
Placenta 13.25 ± 0.65 15.41 ± 1.61 16.11 ± 1.62 15.92 ± 1.20 0.1898 0.4377 0.3547 





Magnesium concentration (mmol/kg dry weight) of various tissues from normal and STZ-induced diabetic dams fed diets with or 
without added chromium (Cr)* 
Tissue: ..................... -............. Treatment Groups ................. . .................. P value ................... 
-Cr-STZ -Cr+STZ +Cr-STZ +Cr+STZ Cr STZ Crx STZ 
Liver 23.93 ± 2.78 25.58 ± 1.41 27.33 ± 1.30 28.37 ±0.87 0.0788 0.4360 0.8597 
n=9 n=IO n=IO n=9 
Kidney 34.27 ± 4.51 31.47 ± 2.13 28.73 ± 1.61 28.70 ± 1.41 0.1219 0.5931 0.6001 
n=9 n=9 n=IO n=IO 
Spleen 35.46 ± 2.79 30.99 ± 1.60 35.73 ± 1.98 35.29 ± 2.82 0.3462 0.3130 0.4061 
n=6 n=6 n=IO n=5 
Heart 24.83 ± 1.90 26.19 ± 1.35 25.84 ± 1.18 25.84 ± 0.77 0.8162 0.6332 0.6329 
n=IO n=9 n=8 n=9 
Fetus 63.09 ± 1.01 62.45 ± 1.74 61.51 ± 1.42 59.72 ± 2.32 0.1878 0.4518 0.7211 
n=IO n=8 n=8 n=7 
Placenta 23.60 ± 1.15 23.52 ± 1.37 24.10 ± 1.18 22.32 ± 1.11 0.7732 0.4555 0.4945 
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Figure IV.I 
Glucose tolerance curves of normal and STZ-induced diabetic dams fed diets with or 
without added chromium (Cr) 
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CHAPTER V 
EFFECT OF CHROMIUM DEPLETION AND DIABETES ON MATERNAL AND 




The hypothesis of this study was that the depletion of the trace mineral chromium (Cr), 
which potentiates the action of insulin in glucose tolerance, exacerbates hyperglycemia and 
the negative outcomes of pregnancy in the streptozotocin (STZ) diabetic pregnant rat 
model perhaps through the regulation of the insulin-like growth factor (IGF) system. To 
determine the effect of Cr depletion and STZ-induced diabetes on the IGF system and fetal 
growth, 40 female Sprague-Dawley rats were randomly assigned one of four treatments in 
a 2X2 factorial design. The four treatments were:· I) very low chromium diet (40 µg 
Cr/kg diet) + citrate buffer injection, 2) very low chromium diet + STZ (30 mg STZ/kg 
body weight) in citrate buffer injection, 3) adequate chromium diet (2 mg Cr/kg diet)+ 
citrate buffer injection, and 4) adequate chromium diet+ STZ in citrate buffer injection. 
At weaning, the rats were housed in Plexiglas cages with plastic grate flooring and had 
free access to their diets and distilled deionized water. Pre-pregnancy diets contained 70 
µg Cr/kg diet. Treatments were applied on day 1 of pregnancy. Dams were sacrificed on 
76 
day 20 of pregnancy. Day 20 maternal and fetal blood glucose, insulin, IGF-I, IGF-II and 
the IGF binding proteins (IGFBP's) were measured. Placenta and fetuses were weighed, 
counted and analyzed for protein and hydroxyproline content. Maternal Cr depletion 
decreased fetal IGF-II concentrations (p<0.05), % protein per fetus (p<0.05) and fetal 
IGF-1 concentrations (p<0.10). STZ-induced diabetes decreased maternal weight gain 
(p<0.02), number of pups per litter (p<0.01), mean pup weight (p<0.02) and maternal 
insulin concentration (p<0.001) and increased maternal blood glucose (p<0.01) and IGF-I 
concentrations (p<0.05) but did not affect fetal hormones or glucose concentrations. 
Placental and fetal hydroxyproline concentrations were not affected by treatments. In 
summary, maternal Cr depletion may negatively affect fetal protein content by decreasing 
fetal IGF-II concentrations while diabetes may negatively affect fetal growth through its 
effect on maternal glucose, insulin and IGF-I. 
Introduction 
Chromium deficiency in man and animals is associated with impaired glucose 
tolerance and a diabetic-like state (1, 2). In humans, chromium supplementation has been 
shown to improve glucose tolerance, lower fasting blood glucose concentrations, 
potentiate the action of insulin and increase HDL cholesterol (I). Chromium deficiency in 
rats leads to retarded growth, decreased glycogen reserves, increased incidence of aortic 
lesions and disturbances in amino acid utilization for protein synthesis (3). However, the 
effect of chromium deficiency on the growth regulating IGF system is unknown. 
Chromium is best known for its insulin potentiating effect. It reduced growth 
hormone-induced insulin resistance and the resultant rise in blood glucose in pigs (4). Pigs 
fed chromium from chromium picolinate had faster glucose disappearance rates in 
response to I.V. glucose tolerance tests and shorter glucose half-life in response to I.V. 
insulin challenge tests when compared to controls (5). In growing-finishing pigs, 
chromium picolinate increased daily gain and percentage of muscling while decreasing 
tenth rib fat and serum cholesterol (6). A recent preliminary study by Ward and 
colleagues (7) indicated that different sources of chromium such as chromium chloride, 
chromium acetate, chromium oxalate, chromium picolinate, chromium nicotinate and 
chromium nicotinate-glycine-cysteine-glutamate did not differ in their effect on growth, 
carcass characteristics, plasma metabolites, insulin or growth hormone concentrations in 
growing, finishing swine. 
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In sows, supplemental.chromium from chromium picolinate increased gestational 
weight gain as well as litter size (8). Furthermore, during gestation, insulin response to 
feeding supplemental chromium in sows was significantly less compared to the response 
by unsupplemented sows. A follow-up study by the same group (9), however, did not find 
a significant effect of chromium on litter size but they did observe that the chromium-
treated group had an average of one more live birth per litter than the controls. The effect 
of supplemental chromium on pregnancy outcome in rats or humans is unknown. 
Although STZ-induced diabetic pregnancies result in impaired fetal growth (10 -
13), little is known about the effect of STZ on the IGF system in pregnancy. The insulin-
like growth factors (IGF's) and their binding proteins (IGFBP's) are necessary for murine 
embryogenesis and fetal growth (14 - 17). Marked fetal growth retardation occurred in 
mice with a hemizygous disruption of the IGF-II gene (18). Both IGF-I and II increased 
incorporation of {3H}thymidine in fetal rat islets (19) and {3H}proline in fetal rat type I 
collagen (20) as well as induced neuronal and muscular differentiation in cocultures of 
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embryonic rat brainstem slices and skeletal muscle fibers (21). Growth-retarded fetal rats 
have decreased IGF-1 and -II gene expression, decreased fetal serum IGF-I and increased 
IGFBP-1 gene expression {22, 23). 
Decreased serum IGF-1, differential gene expression ofIGF-I and IGFBP-1 as well 
as discordant organ specific regulation ofIGF-I mRNA have been observed in diabetic 
male and non-pregnant female rats (24, 25, 26). Diminished IGF-11 expression and 
retarded development were evident in six-day old conceptus of diabetic dams (27). In 
normal rat pregnancies, maternal plasma IGF-I concentrations decrease in conjunction 
with the disappearance ofIGFBP-3 (28). This is associated with an increase in IGFBP-3 
protease activity which promotes the a~ailability ofIGF-1 to rapidly growing and 
differentiating tissues (29). Changes in IGF-I, IGF-11 and their binding proteins during 
normal and diabetic pregnancy might be related to an altered metabolic state and the 
supply of glucose and insulin in both the mother and fetus.which contributes to changes in 
fetal growth. Thus, the objective of this study was to determine the effect of dietary 
chromium depletion and STZ-induced diabetes on maternal and fetal insulin, glucose, IGF-
1, and IGF-11 concentrations, IGF binding protein activity, pregnancy outcome and fetal 
and placental protein and hydroxyproline content. 
Research Design and Methods 
Forty weanling female Sprague Dawley rats were obtained from Sasco Inc. 
(Omaha, NE). The rats were assigned to one of four treatments in a 2 X 2 factorial 
design. The treatments were: 1) very low chromium diet (40 µg chromium/kg diet), 
citrate buffer injection, 2) very low chromium diet, STZ - citrate buffer injection (30 
mg/kg body weight), 3) adequate chromium diet (2 mg chromium/kg diet), citrate buffer 
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injection, and, 4) adequate chromium diet, STZ - citrate buffer injection. All the rats were 
raised in a light and temperature controlled environment in Plexiglas cages with plastic 
grate flooring. The rats were fed semi-purified diets which contained 70 µg chromium/kg 
diet before they were bred. Distilled deionized water was used for drinking water 
throughout the study. Pre-pregnancy and pregnancy diet compositions are outlined in 
Table V.1. The rats were allowed free access to the diets and water which were provided 
in ceramic dishes. Treatments were applied on day 1 of pregnancy which was confirmed 
by the presence of a vaginal plug. The rats were bred at a mean weight of 267 ± 8 (mean 
± SEM) grams and a mean age of 126 ± 3 (mean± SEM) days. The STZ was obtained 
from Sigma Chemical Co. (St. Louis, MO), solubilized and delivered in 1 mL of citrate 
buffer (pH 4.5) and injected into the tail vein. 
The rats were not fasted before necropsy on day 20 of gestation. They were 
anesthetized with a combination ofketamine hydrochloride and xylazine. Fetuses were 
removed by C-section and decapitated. Fetal blood was collected with heparinized 
capillary tubes and pooled in heparinized microcentrifuge tubes. Maternal blood was 
collected by cardiac puncture and mixed gently with 100 units of heparin. The maternal 
blood and tissues were harvested after all the fetuses were collected. Maternal and fetal 
plasma was separated and frozen. Embryo loss was determined by subtracting the number 
of viable fetuses per litter from the total number of corpora lutea observed on the ovaries. 
Analytical methods. Dietary chromium analysis was carried out according to the 
method described by Hill et al (30). Insulin was measured with a commercial rat insulin 
radioimmunoassay kit from Linco Research, Inc. (St. Louis, MO) which, according to the 
manufacturer, has no detectable cross-reactivity with IGF-I or IGF-II. Blood glucose was 
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determined by the glucose oxidase method using Trinder reagent from Ciba Corning 
Diagnostic Corp. (Oberlin,OH). Maternal and fetal IGF was extracted from plasma by the 
formic acid-acetone method of Bowsher and colleagues (31) and concentrations 
determined by a r\dioimmunoassay previously described by Echtemkamp et al (32) and 
Spicer et al (33). Cross-reactivities for IGF-1 in the IGF-11 assay and for IGF-11 in the 
IGF-1 assay were 5.0% and 0.2% respectively. Cross-reactivities for insulin in the IGF-1 
and IGF-11 assay were <0.001% and <0.06% respectively .. IGF binding proteins were 
analyzed by the Western ligand blot method described by Echtemkamp et al (34). Fetal 
protein content was determined with a direct combustion unit (LECO FP428, Leco Corp., 
St. Joseph, Ml) and fetal hydroxyproline determined by the method of Bergman and 
Loxley (35). Statistical analysis was performed using the SAS GLM procedure. Variables 
such as maternal IGF-1 and -II that exhibited heterogeneous variance (determined by SAS 
UNIVARIATE procedure) were log transformed for the analysis of variance. Values 
reported herein are expressed as mean ± SEM. 
Results 
Pregnancy outcome. Adequate chromium diets had a negative effect on litter size 
(p<0.05) and a tendency to decrease maternal weight gain (p<O. l, Table V.2). Diabetes 
has a significant negative effect on maternal weight gain (p<0.05), embryo loss (p<0.01), 
litter size (p<0.01) and average pup weight (p<0.05). Expressed as percent maternal body 
weight, placentas were significantly larger in the adequate chromium group. (Data 
presented in Table IV.S). 
Maternal insulin, glucose, IGF-1 and IGF-11 concentrations are listed in Table V.3. 
Chromium did not significantly affect maternal insulin or glucose concentrations. In 
., 
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contrast, diabetes significantly decreased (p<0.001) maternal plasma insulin such that 
mean plasma insulin concentration for the diabetic group was 0.10 ± 0.02 pmol/L (0.61 ± 
0.47 ng/mL) compared with 0.40 ± 0.08 pmol/L (2.35 ± 2.05 ng/mL) in the non-diabetic 
group. As a result, there was a significant elevation of plasma glucose (p<0.01); mean 
plasma glucose for the diabetic group was 27 ± 3 mmol/L (494 ± 54 mg/dL) compared 
with 18 ± 1 mmol/L (324 ± 17 mg/dL) in the non-diabetic group. 
Dietary chromium did not have an effect (p>O.l) on maternal plasma IGF-1 or 
IGF-II concentrations. Diabetes had a significant effect on maternal plasma IGF-1 
concentration (p<0.05) such that mean IGF-1 concentration for the diabetic dams was 167 
± 66 ng/mL compared with a mean of 129 ± 54 ng/mL in the non-diabetic group. 
Maternal plasma concentrations ofIGF-II were not significantly different among groups 
but there was a tendency for factor interaction to occur (p<O. l ). Within the chromium 
depleted group, diabetes had a tendency to decrease maternal plasma IGF-11 
concentrations but did not have the same effect in the adequate chromium group. 
Figure V. l is a representative autoradiograph from Western ligand blotting of 
maternal and fetal IGF binding proteins. Maternal plasma IGF binding proteins of the 
dams from all treatments were almost undetectable regardless of treatment. No significant 
treatment effect on maternal plasma IGF binding proteins was observed (Table V.4). The 
most prominent IGFBP detected in fetal plasma was a 32 kD species and was not affected 
by treatments. The 45 kD IGFBP, which is IGFBP-3, was present in low amounts in the 
fetal plasma from the diabetic group but not detectable in the non-diabetic group (p<0.05, 
Table V.5). IGFBP activity of the 22 kD species was not consistently observed in all the 
fetal plasma samples and there was no significant difference observed among the treatment 
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groups. 
Fetal insulin, glucose, IGF-1, IGF-11 and fetal protein content are listed in Table 
V.6. Fetal insulin and glucose concentrations were not significantly different among 
groups. There was a tendency for IGF-1 concentrations·to be lower (p<O. I) in the fetuses 
from the chromium depleted dams. Chromium had a significant positive effect on IGF-II 
concentrations (p<0.05) and on fetal protein content (p<0.05). Mean IGF-11 
concentration for the adequate chromium pups was 779 ± 92 ng/mL compared to 697 ± 
85 ng/mL in the chromium depleted pups. Mean protein content for the adequate 
chromium pups was 9.25 ± 0.68 % compared to 8.56 ± 0.76 % in the chromium depleted 
pups. Fetal hydroxyproline concentrations were not significantly affected by chromium or 
STZ (data not shown). 
Discussion 
We observed that dietary chromium decreased the number of pups per litter and 
had a tendency to decrease maternal weight g~n but did not affect mean fetal weights. It 
is possible that intrauterine competition per pup due to increased placental size as a result 
of increased chromium in the diet resulted in decreased litter size. This is in contrast to 
previous studies where a positive effect of chromium on maternal weight gain and litter 
size in sows was observed (8, 9). The sows were supplemented with 200 µg chromium 
from chromium picolinate/kg feed but the total chromium concentration of the feed was 
not specified. In this experiment, we utilized the AIN-76 recommendation of0.55 g 
chromium potassium sulfate/kg mineral mix resulting in a diet containing 2 mg 
chromium/kg diet, a tenfold difference from the sow studies. In view of the preliminary 
studies by Ward and colleagues (7) it is unlikely that the dietary source of chromium may 
have influenced the animals' reproductive performance. Further studies are required to 
determine the precise amount of total dietary chromium needed to optimize reproductive 
performance. 
83 
In this study, fetal IGF-II was greater in the chromium supplemented group as was 
fetal protein content in spite of reduced litter size. It is most likely that chromium 
increased fetal protein through its effect on IGF-II as it has been observed that the 
hemizygous disruption of the IGF-II gene in fetal mice resulted in marked growth 
retardation (24) and that IGF-II stimulated DNA and protein synthesis in numerous fetal 
rat tissues in vitro (25, 26, 27). It is possible that the increase in placental weight and 
subsequent increase in maternal nutrient transfer may have contributed to the increase in 
fetal IGF-II and protein content. Furthermore, we observed an increase in urinary 
hydroxyproline excretion in the dams fed the chromium depletion diet compared to the 
dams fed adequate chromium (3 7) which is a reflection of increased protein breakdown in 
the rats depleted of chromium. 
In agreement with the literature, the toxic effect of STZ on the pancreas and the 
subsequent development of diabetes was demonstrated by the reduced production of 
insulin and the resultant elevation of maternal glucose concentrations. Diabetes also had a 
negative effect on reproductive performance and fetal growth in the present study. As has 
been observed by other researchers ( 18, 19), diabetic dams gained less weight during 
pregnancy, had smaller fetuses, had a greater number of resorptions and a smaller number 
of viable fetuses per litter. Maternal plasma IGF-I concentrations were higher in the 
diabetic group when compared to the non-diabetic group in the present study. These 
hormonal observations have not been documented in diabetic pregnant rats. Hormonal 
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differences were not explained by IGFBP activity in the plasma. These differences may be 
explained by organ specific effects of streptozotocin diabetes on IGF production. 
Streptozotocin-induced diabetes is associated with increased kidney weight, IGF-I 
mRNA (29) and IGF-I concentrations (39, 40). In the present study, we observed an 
increase in kidney weight and a tendency for increased liver weight with diabetes ( data 
presented in Chapter IV). It is possible that increased production of kidney IGF-I 
contributed to the increase in plasma IGF-I concentrations in the present study. 
Measurement of kidney and liver IGF-I mRNA is strongly recommended to determine if 
these contribute to elevated plasma concentrations ofIGF-I during pregnancy complicated 
by STZ-induced diabetes in the rat. 
In this study, diabetes did not affect maternal IGF-II, fetal insulin, fetal glucose, 
fetal IGF-I or IGF-II concentrations but increased IGFBP-3 activity in fetal plasma. This 
is the first demonstration that the fetal IGF system responds to the mother's diabetic 
condition by increasing IGFBP-3 activity. Previously, hepatic IGFBP mRNA 
concentrations have been reported to increase in adult diabetic rats (41, 42). In addition, 
14-day old fetuses of diabetic dams appear to have greater IGFBP~ 1 mRNA expression 
than fetuses of non-diabetic dams (43). Collectively, our results and the observations from 
previous studies support the hypothesis that increased fetal IGFBP secretion may 
contribute to the growth retardation of fetuses from diabetic dams. 
In conclusion, this study demonstrates that although adequate dietary chromium 
has a negative effect on litter size, it does have a positive effect on fetal protein content 
which is associated with its positive effect on fetal IGF-II concentrations. The present 
study also demonstrated that streptozotocin-induced diabetes during pregnancy has 
profound effects on reproductive performance and fetal growth through its effect on 
maternal plasma insulin, glucose and IGF-1. 
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t Prepared in our laboratory. Mineral mix for the treatment diets contained iron chloride 
instead of iron citrate. Mineral mix for the chromium depletion diet did not include the 
addition of chromium potassium sulfate: 
t USB (Cleveland, OH) 
Table V.2 
Pregnancy outcome of normal and STZ-induced diabetic dams fed diets with or without 
added chromium (Cr)* 
Group Maternal weight gain Embryo loss 
(g) (n) 
-Cr-STZ 111±17 3±2 
-Cr+STZ 80±41 6±7 
+Cr-STZ 90±32 4±2 
+Cr+STZ 61±45 8±4 




































Plasma insulin, glucose, IGF-I & IGF-II from normal and STZ-induced diabetic dams fed 
diets with or without added chromium (Cr)* 
Group Insulin Glucose IGF-I 
ng/dL pmol/L mmol/L 
-Cr-STZ 0.54 ±0.09 19.0 ± 3.3 129.0±79.9 
-Cr+STZ 0.12 ± 0.08 26.1 ±3.2 170.6±84.8 
+Cr-STZ 0.30 ± 0.08 17.0 ± 3.2 128.6±15.7 
+Cr+STZ 0.09 ±0.09 28.8 ± 3.3 163.7±42.8 




























IGF binding protein activity from plasma of normal and STZ-induced diabetic dams fed 
diets with or without added chromium (Cr)* 
Group 45 kD 
(ADUt) 
-Cr-STZ 0.329 ± 0.930 
-Cr+STZ 0.000 ± 0.000 
+Cr-STZ 0.000 ± 0.000 
+cr+STZ 0.376 ± 0.994 
32kD 
(ADU) 
2.210 ± 0.795 
2.381 ± 0.931 
2.140 ± 0.618 
2.209 ± 0. 774 
Analysis of variance 
22kD 
(ADU) 
0.520 ± 1.002 
0.721 ± 0.951 
0.185 ± 0.523 





















IGF binding protein activity from plasma of fetuses from normal and STZ-induced diabetic 
dams fed diets with or without added chromium (Cr)* 
Group 45 kD 32 kD 
(ADUt) (ADU) 
-Cr-STZ 0.000 ± 0.000 7.266 ± 3.925 
-Cr+STZ 0.983 ± 1.822 6.249 ± 2.038 
+cr-STZ 0.000 ± 0.000 7.431 ± 2.096 
+Cr+STZ 0.446 ± 1.262 6.666± 1.194 





1.157 ± 1.005 




















Plasma insulin, glucose, IGF-1 & IGF-Il concentrations of fetuses from normal and STZ-
induced diabetic dams fed diets with or without added chromium (Cr)* 
Group Insulin Glucose IGF-1 IGF-Il Protein content 
ng/mL mg/dL ng/mL ng/mL % 
(pmol/L) (mmol/L) 
-Cr-STZ 0.91 ± 0.15 7.7 ± 1.8 48.8±14.5 714.9±93.4 0.085±0.0009 
-Cr+STZ 0.76 ± 0.14 6.8 ± 1.6 50.1±8.7 664.7±62.7 0.086±0.004 
+cr-STZ 1.06 ± 0.13 4.7 ± 1.5 59.6±9.1 799.3±74.2 0. 092±0. 007 
+cr+STZ 0.77 ± 0.14 8.4 ± 1.5 55.2±13.3 742.3±121.3 0.093±0.007 
Analysis of variance 






























2 3 4 5 6 7 8 
A representative ligand blot analysis ofIGFBP activity in maternal and fetal plasma 
collected on day 20 of pregnancy. Lane 1, plasma of a dam from the -Cr-STZ group; 
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lane 2, pooled fetal plasma from pups of the dam in lane 1; lane 3, plasma from a dam 
from -Cr+STZ group; lane 4, pooled fetal plasma from pups of the dam in lane 3; lane 5, 
plasma from a dam from the +Cr-STZ group; lane 6, pooled fetal plasma from pups of the 
dam in lane 5; lane 7, plasma from a dam from the +Cr+STZ group; lane 8, pooled fetal 
plasma from pups of the dam in lane 7. 
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CHAPTER VI 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS 
Summary 
This study was designed to determine the effect of chromium depletion and 
streptozotocin (STZ) - induced diabetes on pregnancy outcome, on maternal carbohydrate 
and lipid metabolism, on the distribution of minerals in maternal tissues, on the placenta 
and fetus, and on the IGF system. Forty weanling female rats were assigned to 4 
treatment groups in a 2 x 2 factorial design. The treatments in this study were: 
1) chromium content of the diet at 40 µg or 2 mg Cr/kg diet given during pregnancy, and 
2) diabetes induced or not induced at the onset of pregnancy by injection of streptozotocin 
(30 mg STZ/k:g body weight) in 0.1 M citrate buffer (pH4.5) vs. citrate buffer alone. All 
rats were fed moderately low chromium diets (70 µg Cr/kg diet) before breeding, and 
were bred at 126 ± 3 days (mean ± SEM) of age. The average breeding weight was 267 ± 
8 grams (mean± SEM). Treatments were initiated on day 1 of pregnancy when a vaginal 
plug was observed. Glucose tolerance tests were given on day 18 of pregnancy. All rats 
were necropsied on day 20 for tissue and blood collection. Maternal and fetal plasma 
were analyzed for glucose, insulin, total triglycerides, cholesterol, non-esterified free fatty 
acids, P-hydroxybutyrate, IGF-I, IGF-II concentrations and the IGF binding protein 
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activity. Maternal kidney, liver, spleen, heart, and the placenta and fetuses were weighed 
and analyzed for calcium, magnesium, iron, copper, zinc, chromium and manganese 
concentrations. 
Maternal plasma insulin, glucose, fructosamine, glucose tolerance, and other 
metabolites such as triglycerides, cholesterol, free fatty acids and J3-hydroxybutyrate were 
not significantly affected by chromium depletion. Maternal chromium depletion decreased 
placenta size when expressed as percent maternal body weight, had a tendency to increase 
maternal weight gain, significantly increased litter size but did not affect mean pup 
weights. Chromium depletion decreased concentrations of chromium and zinc while 
increasing manganese concentration in the kidneys. Maternal chromium depletion also 
decreased copper concentrations of the heart. Maternal chromium depletion decreased 
fetal IGF-II concentrations, percent protein per fetus and had a tendency to decrease fetal 
IGF-I concentrations. 
Diabetes decreased maternal weight gain, enlarged maternal kidneys and spleens, 
and increased fetal loss and therefore decreased litter size, and, decreased fetal weight. 
Diabetes significantly decreased plasma insulin concentrations increasing plasma glucose 
and triglycerides. Diabetes thus resulted in severe glucose intolerance as demonstrated by 
elevated tolerance curves, larger areas under these curves and lower insulin to glucose 
ratios. Diabetes increased liver and kidney concentrations of copper and zinc and had a 
tendency to decrease fetal chromium concentrations. Streptozotocin induced diabetes 
increased maternal IGF-I concentrations but did not affect fetal hormones or glucose 
concentrations. Maternal IGFBP activity was almost nil while only fetuses from diabetic 
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dams had the 45kD IGFBP. Placental and fetal hydroxyproline content were not affected 
by treatments. 
Several significant interaction effects between chromium and diabetes were 
observed. Within the adequate chromium group, diabetes increased plasma non-esterified 
free fatty acid concentrations but not in the chromium depleted group. Maternal liver 
protein was increased by diabetes in the chromium depleted group but not in the adequate 
chromium group. Within the chromium depleted group, diabetes increased fetal 
manganese concentrations but within the adequate chromium group, diabetes decreased 
fetal manganese concentrations. 
Conclusions 
The first objective of this study was to determine the effect of chromium depletion 
and diabetes induced during pregnancy on glucose tolerance, and on circulating total 
cholesterol, total triglycerides, non-esterified fatty acids and J3-hydroxybutyrate 
concentrations. Based on the null hypothesis that chromium depletion and diabetes during 
pregnancy would not affect maternal glucose tolerance or total plasma cholesterol, 
triglycerides, non-esterified fatty acids and J3-hydroxybutyrate concentrations, the 
following conclusions were drawn. Chromium depletion had no effect on glucose 
tolerance, total plasma triglycerides, cholesterol or J3-hydroxybutyrate. Diabetes had a 
detrimental effect on maternal glucose tolerance, and increased total plasma triglycerides 
but not cholesterol or J3-hydroxybutyrate. Diabetes increased non-esterified fatty acid 
concentrations only in dams receiving an adequate chromium diet but not in those 
receiving a chromium depletion diet. 
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The second objective of this study was to determine the effect of chromium 
depletion and diabetes induced during pregnancy on plasma insulin, glucose, IGF-1, IGF-
II, IGF binding protein activity, maternal weight gain and pregnancy outcome. Based on 
the null hypothesis that chromium depletion and diabetes during pregnancy would not 
affect maternal plasma insulin, glucose, IGF-1, IGF-II, IGF binding protein activity, 
maternal weight gain or pregnancy outcome, the following conclusions were drawn. 
Chromium depletion had a positive effect on litter size· and a tendency to increase 
gestational weight gain but did not affect maternal plasma, insulin, IGF-1, IGF-11, IGF 
binding protein activity or fetal weight. Diabetes had an adverse effect on maternal 
insulin, glucose, increased plasma IGF-1, decreas~d gestational weight gain, litter size and 
fetal weight but did not affect IGF-II concentrations or IGF binding protein activity. 
Chromium depletion and diabetes had an interactive effect on maternal liver protein 
concentration such that within the chromium depleted group, diabetes increased maternal 
liver protein concentration but did not have the same effect in the adequate chromium 
group. 
The third objective of this study was to determine the effect of chromium depletion 
and diabetes during pregnancy on fetal plasma insulin, glucose, IGF-1, IGF-II, IGF binding 
proteins, fetal weight, fetal protein and hydroxyproline concentrations. Based on the null 
hypotheses that chromium depletion and diabetes during pregnancy would not affect fetal 
plasma insulin, glucose, IGF-1, IGF-II, IGF binding protein activity, fetal weight, fetal 
protein or hydroxyproline concentration, the following conclusions were drawn. 
Chromium depletion decreased fetal plasma IGF-II and fetal protein concentration and had 
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a tendency to decrease fetal IGF-I concentrations but not plasma insulin, glucose, IGF 
binding protein activity, fetal weight or hydroxyproline concentrations. Maternal diabetes 
decreased fetal weight and promoted IGFBP-3 activity in fetal plasma but it did not affect 
fetal plasma insulin, glucose, IGF-1, IGF-II, fetal protein or hydroxyproline 
concentrations. 
The fourth objective of this study was to determine the effect of chromium 
depletion and diabetes during pregnancy on macromineral and trace mineral 
concentrations in the liver, kidney, spleen, heart, placenta and fetuses of the experimental 
animals. Based on the null hypotheses that chromium depletion and diabetes during 
pregnancy would not affect macromineral and trace mineral concentrations in the liver, 
kidney, spleen, heart, placenta and fetuses of the experimental animals, it was concluded 
that chromium depletion decreased kidney chromium and zinc, decreased heart copper and 
increased kidney manganese concentrations but did not affect the distribution of calcium 
or magnesium in the tissues. Diabetes on the other hand increased kidney and liver copper 
and zinc but did not affect the distribution of calcium, magnesium, iron or chromium in the 
tissues. Chromium depletion and diabetes had interactive effects on the distribution of 
chromium in the maternal heart and manganese in the fetus. The adequate chromium non-
diabetic group had a significantly greater concentration of chromium in the heart 
compared to all the other groups. Within the chromium depleted group, diabetes 
increased fetal manganese concentrations while within the adequate chromium group, 
diabetes decreased fetal manganese concentrations. 
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Recommendations 
Further study is recommended to determine the effects of dietary chromium on 
glucose tolerance and insulin sensitivity in pregnancy. Perhaps, a different animal model 
such as the spontaneously diabetic BB/Wistar rat, the BHE rat or second generation rats 
from STZ treated dams might be more suitable than the STZ-induced diabetic dam in that 
there would be no artificial or chemical destruction of ~-cell function. As we have seen in 
this study, streptozotocin is very toxic to the pancreas so that insulin production is 
markedly decreased. Another alternative would be to give endogenous insulin during 
diabetes in pregnancy and base conclusions on the effect of the treatments on insulin 
requirement to maintain normal glucose control. 
Diet composition was also different before and after pregnancy was induced. It is 
possible that the chromium depleted rats had larger litter size because they were subjected 
to the least change and may have eaten more to compensate for the lack of chromium in 
the diet. Therefore, food intake measurements may be a valuable piece of data to consider 
in similar experiments. Furthermore, the diets changed from 10% sucrose - 43% 
cornstarch - 10% dextrose before pregnancy to 50% sucrose - 15% cornstarch after 
pregnancy was induced. This drastic change in simple and complex carbohydrate 
concentrations may have affected outcomes. Unfortunately, until low chromium complex 
carbohydrates are made available, the formulation for low chromium diets will remain a 
problem. 
The interaction effects that surfaced in this study warrant further investigation. 
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The changes in the distribution of manganese concentrations in the fetus and chromium in 
the maternal heart need to be explored to determine the extent of these changes and how 
chromium in the diet and diabetes affect each other in this respect. Histological studies as 
well as organ function studies and DNA analysis are recommended. 
Implications 
It was difficult to assess our results adequately because similar types of data were 
either limited or not available for comparison. Nevertheless, practical implications can be 
garnered from this study. It is clear that different levels of chromium in the diet can affect 
fetal physiology as well as mineral distribution in various tissues during pregnancy in the 
rat. Together with the presence of diabetes, these possibly adverse conditions could be 
exacerbated. Based on our results, chromium supplementation of the diet for individuals 
with impaired glucose tolerance or for pre-gestational or gestational diabetic women may 
not be a safe. Further research is necessary to determine the safety and efficacy of 
chromium supplementation especially during pregnancy. Chromium supplements such as 
chromium picolinate which are categorized as a food supplements are readily available in 
grocery stores, pharmacies and health food stores. Because of the lack of government 
regulation, quality, purity and safety requirements and standards such as those followed by 
the Food and Drug Administration for the regulation of drugs, are not required for food 
supplements. Thus, chromium and other mineral supplements and plant extracts with 
pharmacological properties and effects are readily available. It is necessary to promote 
caution in the self-prescribed use not only of chromium supplements but also of other 
mineral supplements as well until more definitive results are observed. 
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Mineral Mix Compositions 
Components: - Cr diet + Cr diet: 
(g/kg mix) (g/kg mix) 
Calcium phosphate, dibasic 500.0 500.0 
Sodium chloride 74.0 74.0 
Potassium citrate, monohydrate 220.0 220.0 
Potassium sulfate 52.0 52.0 
Magnesium oxide 24.0 24.0 
Manganous carbonate 0.65 0.65 
Ferrous chloride 3.56 3.56 
Zinc carbonate 1. 60 1.60 
Cupric carbonate 0.30 0.30 
Potassium iodate 0.01 0.01 
Sodium selenate 0.01 0.01 
Chromium potassium sulfate 0.00 0.55 
Sucrose 121.19 120.64 
Appendix C 
Reagents for Hydroxyproline Analysis 
a. Oxidant solution buffer: 
Sodium acetate (3H20) 
Trisodium citrate (2H20) 
Citric acid (H20) 
2-Isopropanol 





Add to make IL total volume. 
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Weigh and pour dry ingredients into a 1 L volumetric flask. Add the isopropanol followed 
by water to volume. Place mixing bar in the flask and mix on low heat until all 
components are in solution. When cooled, store buffer in a clean opaque plastic bottle. 
b. Oxidant solution: After all samples and standards have been aliquoted and the 
Ehrlich's reagent prepared, weigh 0. 7 g chloramine-T and add water to make 10 mL. Add 
40 mL buffer solution as described above. Mix gently and cover with foil. 
c. Ehrlich's reagent: To make 100 mL of reagent, weigh 17.6 grams para-
dimethylaminobenzaldehyde (PDAB). Dissolve PDAB in 40.8 grams of 60% perchloric 
acid. Add isopropanol to make 100 mL. Cover with foil. 
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